[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 117
1. Sanka RK, Eagle RC Jr, Wojno TH, Neufeld KR, Grossniklaus HE: Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma. Ophthalmology; 2010 Feb;117(2):343-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.
  • PURPOSE: To report the clinicopathologic features of 3 patients with CD30(+) lymphoid proliferations of the eyelid.
  • PARTICIPANTS: Patients with cutaneous CD30(+) lymphoproliferative lesions of the eyelid.
  • METHODS: Three patients with CD30(+) non-mycosis fungoides T-cell lymphoid infiltrates of the eyelid were identified.
  • RESULTS: The patients included an 81-year-old man, an 18-year-old man, and a 42-year-old woman with CD30(+) lymphoid proliferations of the eyelid and adjacent soft tissue.
  • The second patient had an isolated multinodular lesion of the eyelid that was classified as cutaneous anaplastic large cell lymphoma (cALCL).
  • The third patient presented with eyelid edema with an underlying mass and was found to have widely disseminated anaplastic large cell lymphoma (ALCL).
  • CONCLUSIONS: The CD30(+) lymphoid proliferations represent a spectrum of conditions ranging from indolent LyP, to moderately aggressive cALCL, to highly aggressive ALCL.
  • Interpretation of the pathologic findings in CD30(+) lymphoid proliferations is based in part on clinical findings.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2009 Jan-Feb;25(1):63-5 [19273934.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):194-205 [10384116.001]
  • [Cites] Arch Ophthalmol. 1999 Jul;117(7):955-8 [10408463.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2854-61 [10515889.001]
  • [Cites] Br J Ophthalmol. 2005 Mar;89(3):385 [15722323.001]
  • [Cites] Int J Dermatol. 2006 Jun;45(6):766-9 [16796648.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1898-904 [17392826.001]
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):766-70 [10792229.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] J Cutan Pathol. 2000 Sep;27(8):392-9 [10955685.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] J Cutan Pathol. 2001 Oct;28(9):453-9 [11553311.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):741-60 [11564061.001]
  • [Cites] J Cutan Pathol. 2002 May;29(5):295-300 [12100631.001]
  • [Cites] Eur J Ophthalmol. 2002 Nov-Dec;12(6):542-6 [12510725.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):199-204 [12579989.001]
  • [Cites] Arch Ophthalmol. 2003 Apr;121(4):568-70 [12695256.001]
  • [Cites] J Pathol. 2003 Jun;200(2):240-8 [12754745.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Blood. 1986 Nov;68(5):1042-9 [3490284.001]
  • [Cites] J Fr Ophtalmol. 1987;10(3):247-52 [3611612.001]
  • [Cites] Blood. 1988 Jul;72(1):234-40 [3260522.001]
  • [Cites] Leukemia. 1989 Dec;3(12):866-70 [2555633.001]
  • [Cites] Histopathology. 1993 Aug;23(2):127-35 [8406384.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:25-30 [8172812.001]
  • [Cites] Br J Ophthalmol. 1995 Apr;79(4):391-2 [7742293.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3437-41 [8605362.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):221-35 [8806956.001]
  • [Cites] Am J Ophthalmol. 1997 Jul;124(1):105-7 [9222241.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Am J Ophthalmol. 1998 May;125(5):717-9 [9625564.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1223-30 [9824099.001]
  • (PMID = 19969358.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY006360-24; United States / NEI NIH HHS / EY / P30 EY006360; United States / NEI NIH HHS / EY / P30 EY006360-24; United States / NEI NIH HHS / EY / P30 EY06360
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS164186; NLM/ PMC2830810
  •  go-up   go-down


2. Yaakup H, Sagap I, Fadilah SA: Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell phenotype. Singapore Med J; 2008 Oct;49(10):e289-92
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell phenotype.
  • Primary oesophageal lymphoma is a very rare entity, with fewer than 30 reported cases worldwide.
  • Most of the oesophageal lymphomas are diffuse large B-cell type, with only one reported case of anaplastic large cell lymphoma (ALCL) of T-cell phenotype.
  • We describe the first case of primary oesophageal Ki (CD30)-positive ALK+ALCL of T-cell phenotype in a 34-year-old immunocompetent woman, who presented with a two-year history of dysphagia.
  • She was treated with chemotherapy and endoscopic oesophageal dilations and stenting, resulting in complete remission of the lymphoma and resolution of the dysphagia.
  • She then underwent autologous peripheral blood haematopoietic stem cell transplantation and remained disease-free two years after the diagnosis.
  • [MeSH-major] Antigens, CD30 / biosynthesis. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Adult. Disease-Free Survival. Endoscopy / methods. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Phenotype. Receptor Protein-Tyrosine Kinases. Remission Induction. T-Lymphocytes / metabolism. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18946602.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


3. Nandini A, Mysore V, Sacchidanand S, Chandra S: Primary cutaneous anaplastic large cell lymphoma arising from lymphomatoid papulosis, responding to low dose methotrexate. J Cutan Aesthet Surg; 2009 Jul;2(2):97-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma arising from lymphomatoid papulosis, responding to low dose methotrexate.
  • CD30+ cutaneous lymphoproliferative disorders (CLPDs) present variable clinical and histological manifestations.
  • We report here a case of an adult male patient who progressed from lymphomatoid papulosis to anaplastic large cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20808598.001).
  • [ISSN] 0974-5157
  • [Journal-full-title] Journal of cutaneous and aesthetic surgery
  • [ISO-abbreviation] J Cutan Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2918348
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / cutaneous lymphoproliferative disorders / lymphomatoid papulosis / methotrexate
  •  go-up   go-down


Advertisement
4. Dilnawaz M: Cutaneous CD30 positive anaplastic large cell lymphoma. J Coll Physicians Surg Pak; 2010 Aug;20(8):547-8
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD30 positive anaplastic large cell lymphoma.
  • An adult Caucasian male presented with a solitary abscess-like lesion on his left thigh.
  • Histology confirmed it to be a CD30 positive anaplastic large cell lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Humans. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20688023.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


5. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med; 2010 Nov 4;363(19):1812-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
  • BACKGROUND: Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30.
  • Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity.
  • To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35).
  • METHODS: In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.
  • Patients had received a median of three previous chemotherapy regimens (range, one to seven), and 73% had undergone autologous stem-cell transplantation.
  • CONCLUSIONS: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study.
  • [MeSH-major] Hodgkin Disease / drug therapy. Immunoconjugates / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30. Chemokine CCL17 / blood. Dose-Response Relationship, Drug. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Peripheral Nervous System Diseases / chemically induced. Recurrence. Remission Induction. Young Adult


6. Slotosch CM, Hörster S, Hertl M, Schultz E: [Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis]. Hautarzt; 2010 Jun;61(6):511-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis].
  • [Transliterated title] Neutrophilenreiches, CD30+ anaplastisches T-Zell-Lymphom in Assoziation mit einer lymphomatoiden Papulose.
  • The 2005 EORTC/WHO classification includes three CD30+ lymphoproliferative disorders:.
  • 1) primary cutaneous anaplastic large cell lymphoma, 2) lymphomatoid papulosis and 3) borderline cases.
  • We present a 40-year-old female who initially presented with a neutrophil-rich, anaplastic CD30+ T cell lymphoma followed by lymphomatoid papulosis.
  • [MeSH-major] Facial Neoplasms / diagnosis. Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Lymphomatoid Papulosis / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neutrophils / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Diagnosis, Differential. Eosinophils / pathology. Female. Humans. Lymphocytes / pathology. Methotrexate / therapeutic use. PUVA Therapy

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2003 Mar;148(3):580-6 [12653754.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):478-82 [10989649.001]
  • [Cites] J Am Acad Dermatol. 1993 Jun;28(6):973-80 [8388410.001]
  • [Cites] Am J Surg Pathol. 1995 Apr;19(4):407-16 [7694942.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):244-6 [9989857.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • (PMID = 19536511.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Ma L, Katz Y, Sharan KP, Schwarting R, Kim AS: Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality? Int J Clin Exp Pathol; 2010;4(1):100-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality?
  • The World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissue, 2008 edition, states that anaplastic large cell lymphoma (ALCL) is "consistently negative for Epstein-Barr virus (EBV)".
  • Herein we report a case of an immunocompetent 35-year-old male who presented with hemophagocytic syndrome secondary to lymphoma for which diagnostic material consisted solely of a bone marrow biopsy.
  • The biopsy demonstrated large anaplastic cells which were uniformly positive for surface CD3, CD30 (strong membranous and Golgi expression), CD45, TIA-1 and Granzyme B but negative for ALK-1.
  • In-situ hybridization was strongly positive for EBER in the large neoplastic cells.
  • The uniformity of CD30 expression and positivity for cytotoxic markers on the anaplastic tumor cells raised the diagnostic possibility of an EBV-associated ALCL, ALK-.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / isolation & purification. Lymphoma, Large-Cell, Anaplastic / virology. Tumor Virus Infections / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Bone Marrow Cells / pathology. Bone Marrow Cells / virology. Fatal Outcome. Humans. Male. RNA, Viral / isolation & purification. World Health Organization

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Blood. 2010 Nov 25;116(22):4546-59 [20699441.001]
  • [Cites] J Pathol. 2000 Aug;191(4):400-6 [10918215.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Laryngoscope. 2000 Dec;110(12):2081-4 [11129025.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):920-5 [11286472.001]
  • [Cites] J Virol. 2002 Apr;76(8):4080-6 [11907247.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):146-52 [11957137.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):205-12 [12579990.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):455-9 [15116326.001]
  • [Cites] J Clin Pathol. 1987 Sep;40(9):995-1015 [3312308.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):562-7 [1318268.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1315-25 [1318639.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):457-65 [1323222.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2666-73 [1668608.001]
  • [Cites] J Pathol. 1992 Nov;168(3):307-15 [1335046.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1612-8 [8123852.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):42-9 [7802137.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):542-6 [7577580.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1045-55 [8562929.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):210-5 [9071728.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1420-32 [9414185.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1415-9 [9416699.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Am J Hematol. 1999 Mar;60(3):205-14 [10072112.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1184-200 [10524519.001]
  • [Cites] Pathol Res Pract. 2004;200(10):669-79 [15648604.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):323-32 [16280661.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Int J Dermatol. 2006 Nov;45(11):1312-6 [17076712.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1859-64 [17149964.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):887-95 [17509986.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):314-22 [17638668.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Clin Pathol. 2008 Sep;130(3):343-51 [18701406.001]
  • [Cites] J Mol Diagn. 2008 Nov;10(6):502-12 [18832464.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Am J Dermatopathol. 2008 Dec;30(6):567-71 [19033930.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:272-9 [19074096.001]
  • [Cites] Oncogene. 2009 Nov 12;28(45):3997-4008 [19718051.001]
  • [Cites] Blood. 2010 Nov 11;116(19):3695-704 [20671118.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • (PMID = 21228932.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC3016108
  • [Keywords] NOTNLM ; ALK / Epstein-Barr virus / anaplastic large cell lymphoma
  •  go-up   go-down


8. Mencía-Gutiérrez E, Gutiérrez-Díaz E, Salamanca J, Martínez-González MA: Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL). Int J Dermatol; 2006 Jun;45(6):766-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL).
  • AIM: To report an unusual case of cutaneous presentation on the eyelid of systemic (or nodal), CD30+, anaplastic large-cell lymphoma (ALCL).
  • RESULTS: The histopathologic and immunohistochemical diagnosis was ALCL, T-cell phenotype, strongly positive for CD43 and CD30, and negative for CD3, anaplastic lymphoma kinase (ALK), and B-cell antigens.
  • CONCLUSIONS: Primary, systemic, CD30+, ALK-negative, ALCL presentations generally have a poor prognosis and tend to occur in older individuals, although the clinical outcome is highly variable and difficult to predict in individual cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD30 / analysis. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796648.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


9. Martín JM, Ricart JM, Monteagudo C, Alcácer J, Pinazo I, Tomás L, Rausell N, Jordá E: Primary cutaneous CD30+ anaplastic large-cell lymphomas mimicking keratoacanthomas. Clin Exp Dermatol; 2007 Nov;32(6):668-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large-cell lymphomas mimicking keratoacanthomas.
  • Primary cutaneous anaplastic large cell lymphoma (ALCL) may be associated with keratoacanthoma (KA)-like epithelial hyperplasia and dense eosinophilic and neutrophilic infiltrates.
  • Diagnosis in such cases is challenging both clinically and histologically, because the large atypical lymphoid cells may be obscured by the massive infiltrate of eosinophils and neutrophils, or confused with invasive squamous cell carcinoma or KA.
  • We recently encountered two cases of CD30+ ALCL presenting with a KA-like tumour on the eyelid and nose, respectively.
  • [MeSH-major] Facial Neoplasms / diagnosis. Keratoacanthoma / diagnosis. Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Eyelid Neoplasms / diagnosis. Eyelid Neoplasms / pathology. Female. Humans. Male. Middle Aged. Nose Neoplasms / diagnosis. Nose Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17953637.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Madray MM, Greene JF Jr, Butler DF: Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol; 2008 Oct;65(10):1378-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
  • OBJECTIVE: To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.
  • Biopsy showed primary, cutaneous, anaplastic large-cell lymphoma.
  • CONCLUSIONS: Several T-cell-mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum.
  • We report the association of a T-cell malignancy with the use of glatiramer acetate.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Leg / pathology. Lymphoma, Large-Cell, Anaplastic / chemically induced. Peptides / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antigens, CD30 / biosynthesis. Biomarkers. Biopsy. Female. Glatiramer Acetate. Humans. Multiple Sclerosis, Relapsing-Remitting / drug therapy. Neoplasm, Residual. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852356.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers; 0 / Immunosuppressive Agents; 0 / Peptides; 5M691HL4BO / Glatiramer Acetate
  •  go-up   go-down


11. Kim YC, Yang WI, Lee MG, Kim SN, Cho KH, Lee SJ, Lee MW, Koh JK: Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. Int J Dermatol; 2006 Nov;45(11):1312-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
  • AIM: To elucidate the possible association of EBV with CD30+ anaplastic large cell lymphoma (ALCL) involving the skin and lymphomatoid papulosis (LyP) in South Korea.
  • METHODS: In situ hybridization for EBV-encoded small RNA (EBER) and immunohistochemistry including viral latent membrane protein-1 (LMP-1) were performed on formalin-fixed, paraffin-embedded skin specimens of 26 cases of LyP and 16 cases of CD30+ ALCL involving the skin which were selected from six university hospital medical centers in South Korea.
  • RESULTS: In situ hybridization studies showed positivity of the neoplastic cells for EBER in two of 16 cases of CD30+ ALCL and in none of the cases of LyP.
  • One EBER-positive case was cutaneous CD30+ ALCL with concurrent lymph node involvement.
  • The other was CD30+ ALCL involving the skin and other organs, including lymph nodes, bone, lung, and spleen.
  • Immunostaining for LMP-1 was also positive only for the two cases of EBER-positive CD30+ ALCL.
  • CONCLUSION: LyP and primary cutaneous CD30+ ALCL are very rarely associated with EBV in South Korea.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / growth & development. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD30 / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Korea. Male. Middle Aged. RNA, Viral / genetics. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076712.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr virus encoded RNA 1; 0 / Epstein-Barr virus encoded RNA 2; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


12. Ishii K, Yamamoto Y, Nomura S: [CD30-negative diffuse large B-cell lymphoma expressing ALK]. Rinsho Ketsueki; 2005 Jul;46(7):501-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD30-negative diffuse large B-cell lymphoma expressing ALK].
  • An open-abdominal lymph node biopsy was performed from which a diagnosis of anaplastic large cell lymphoma was made.
  • He underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from his HLA-matched sister while in non-CR in November 2002.
  • The tumor cells were ALK-positive, CD30-negative and JH rearrangement was detected, and were therefore classified as diffuse large B-cell lymphoma with expression of ALK according to the WHO classification, though they differed from this subtype in some points.
  • Although this case was refractory for chemotherapy with a complex karyotype, the graft-versus-lymphoma effect might have contributed to the sustained CR following the PBSCT.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Protein-Tyrosine Kinases
  • [MeSH-minor] Adult. Antigens, CD30. Combined Modality Therapy. Fatal Outcome. Humans. Male. Peripheral Blood Stem Cell Transplantation. Peripheral Vascular Diseases / etiology. Receptor Protein-Tyrosine Kinases. Transplantation, Homologous

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440742.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


13. Kneile JR, Tan G, Suster S, Wakely PE Jr: Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma. Histopathology; 2006 Jun;48(7):855-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma.
  • AIMS: Undifferentiated nasopharyngeal non-keratinizing carcinoma (UNPC), formerly known as lymphoepithelioma, frequently metastasizes at an early stage to regional lymph nodes and, thus, may be difficult to distinguish from Hodgkin's lymphoma (HL) or anaplastic large cell lymphoma (ALCL).
  • CD30 expression is a useful diagnostic stain in both HL and ALCL, but its expression in UNPC deserves clarification.
  • The aim of this study was to evaluate CD30 expression in UNPC and lymphoepithelioma-like carcinoma (LELC) from other anatomic locations and compare it with ALCL and squamous cell carcinoma (SCC).
  • METHODS AND RESULTS: CD30 immunoreactivity was examined in 38 cases of primary or metastatic UNPC, six cases of LELC, 10 cases of SCC and seven cases of ALCL.
  • CD30 immunoreactivity was observed in four of 38 (10.5%) cases of UNPC.
  • CD30 staining was absent in all cases of LELC (0/6) and SCC (0/10).
  • All cases of ALCL (7/7) were strongly positive for CD30.
  • CONCLUSIONS: The majority of cases of UNPC are immunohistochemically negative for CD30; however, a small subset of cases expresses CD30 antigen.
  • These findings provide additional evidence that CD30 expression is not restricted to neoplasms of lymphoid origin.
  • This should be taken into consideration when interpreting CD30 immunohistology and the possibility of UNPC.
  • [MeSH-major] Antigens, CD30 / biosynthesis. Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged


14. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, Keler T, Graziano R, Blanset D, Yellin M, Fischkoff S, Assad A, Borchmann P: Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol; 2007 Jul 1;25(19):2764-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.
  • PURPOSE: MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models.
  • To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed.
  • Twenty-one patients--16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell lymphoma--were enrolled.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Hodgkin Disease / therapy. Immunotherapy / methods. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / iratumumab
  •  go-up   go-down


15. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL, Gopal AK: A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol; 2009 Jul;146(2):171-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
  • SGN-30, a chimeric anti-CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Hodgkin Disease / therapy. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Anti-Idiotypic / blood. Chimerin Proteins / blood. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Young Adult


16. Kalinova M, Krskova L, Brizova H, Kabickova E, Kepak T, Kodet R: Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. Leuk Res; 2008 Jan;32(1):25-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
  • Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of malignant lymphoproliferative diseases with a consistent expression of the cytokine receptor CD30.
  • Real-time quantitative RT-PCR (RQ-RT-PCR) of NPM/ALK and CD30 gene expression was employed to analyze minimal residual disease (MRD) in 10 patients with NPM/ALK positive ALCL in 79 follow-up bone marrow (BM) and/or peripheral blood (PB) samples.
  • In all BM samples from relapses and/or closely before a relapse, BM samples revealed NPM/ALK and CD30 positivity in at least one of the iliac BM trephines.
  • We found that RQ-RT-PCR of the CD30 expression is not suitable for MRD detection--only two relapses were accompanied by an increase of the CD30 level above a level which was detected in BM/PB samples from healthy individuals.
  • [MeSH-major] Antigens, CD30 / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Neoplasm, Residual / genetics. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Expression. Humans. Male. Polymerase Chain Reaction. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320171.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


17. Perez K, Castillo J, Dezube BJ, Pantanowitz L: Human Immunodeficiency Virus-associated anaplastic large cell lymphoma. Leuk Lymphoma; 2010 Mar;51(3):430-8
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human Immunodeficiency Virus-associated anaplastic large cell lymphoma.
  • Anaplastic large cell lymphoma (ALCL) is a distinct subtype of peripheral T-cell lymphoma (PTCL) characterized by the expression of CD30 in lymphoma cells.
  • Like aggressive B-cell non-Hodgkin lymphoma, the risk of developing PTCL is also increased in the setting of HIV infection.
  • Analysis of these cases showed that this group of HIV-infected patients was on average 38 years of age with a male-to-female ratio of 4:1, and a reported median CD4 cell count of 83 cells/mm(3).
  • HIV-associated ALCL cells rarely expressed anaplastic lymphoma kinase.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD30 / biosynthesis. CD4-Positive T-Lymphocytes / metabolism. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Prognosis


18. Yamane N, Kato N, Nishimura M, Ito M, Yanagi T, Osawa R: Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide. Clin Exp Dermatol; 2009 Jul;34(5):e56-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide.
  • Primary cutaneous CD30+ anaplastic large-cell lymphoma (PCALCL) in adults is rare, and the prognosis is generally excellent.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Lymphoma, Primary Cutaneous Anaplastic Large Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Etoposide / therapeutic use. Female. Humans. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438576.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 10
  •  go-up   go-down


19. Lim ZY, Grace R, Salisbury JR, Creamer D, Jayaprakasam A, Ho AY, Devereux S, Mufti GJ, Pagliuca A: Cardiac presentation of ALK positive anaplastic large cell lymphoma. Eur J Haematol; 2005 Dec;75(6):511-4
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac presentation of ALK positive anaplastic large cell lymphoma.
  • Cardiac involvement as an initial presentation of malignant lymphoma is a rare occurrence.
  • Histological and immunophenotypic review of the initial cardiac biopsy revealed features consistent with a diagnosis of CD30, ALK1 positive anaplastic large cell lymphoma (ALCL).
  • The overall prognosis of cardiac lymphoma remains poor, which may be due to the often late presentation of the tumour.
  • [MeSH-major] Activin Receptors, Type I. Heart Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Activin Receptors, Type II. Adult. Biopsy / methods. Humans. Immunohistochemistry / methods. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313264.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type I; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


20. Muzzafar T, Wei EX, Lin P, Medeiros LJ, Jorgensen JL: Flow cytometric immunophenotyping of anaplastic large cell lymphoma. Arch Pathol Lab Med; 2009 Jan;133(1):49-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric immunophenotyping of anaplastic large cell lymphoma.
  • CONTEXT: Anaplastic large cell lymphoma (ALCL) is usually diagnosed by histologic and immunohistochemical analysis.
  • Anaplastic lymphoma kinase (ALK) was assessed by using immunohistochemistry.
  • In the remaining 19 cases (11 ALK(+), 8 ALK(-)), all were positive for CD30 and CD45.
  • Anaplastic large cell lymphoma cells were large and usually CD45 bright, with many or most cells falling in the region of monocytes on the CD45/side scatter plot.
  • The frequencies of T-cell antigen expression in ALK(+) cases were CD2, 67%; CD7, 60%; CD3, 45%; CD4, 33%; CD5, 14%; and CD8, 14%.
  • In ALK(-) cases, the frequencies of the T-cell antigen expression were CD2, 100%; CD3, 50%; CD4, 40%; CD7, 40%; CD5, 25%; and CD8, 20%.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biopsy, Fine-Needle. Female. Humans. Immunohistochemistry. Male. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123736.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


21. Cai G, Inghirami G, Moreira A, Sen F: Primary hepatic anaplastic large-cell lymphoma diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol; 2005 Aug;33(2):106-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic anaplastic large-cell lymphoma diagnosed by fine-needle aspiration biopsy.
  • Anaplastic large-cell lymphoma (ALCL) presenting as primary hepatic lymphoma is exceedingly rare.
  • The aspirate smears revealed many loosely dispersed, large atypical cells, some of them with kidney-/horseshoe-shaped and doughnut-shaped nuclei and abundant amphophilic cytoplasm.
  • These large atypical cells displayed T-cell immunophenotype and were immunoreactive with CD30 antibody.
  • [MeSH-major] HIV Seropositivity / pathology. Liver Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Biopsy, Fine-Needle. Humans. Male


22. Asano N, Suzuki R, Matsuo K, Kagami Y, Ishida F, Tamaru JI, Jin GS, Sato Y, Shimoyama Y, Yoshino T, Morishima Y, Nakamura S: Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma. Histopathology; 2007 May;50(6):705-15
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma.
  • AIMS: The Revised European American Lymphoma classification uses the term Hodgkin's-like anaplastic large cell lymphoma (HD-like ALCL) for borderline cases with features of both anaplastic large cell lymphoma (ALCL) and classical Hodgkin's lymphoma (HL).
  • METHODS AND RESULTS: Subjects were 59 patients with HD-like ALCL, defined by nodal presentation without mediastinal bulky lesions, T- or null-cell phenotype, CD30+ anaplastic lymphoma kinase (ALK)- phenotype and by confluent sheets or nodules of large cells mimicking classic Hodgkin and Reed-Sternberg cells.
  • Multivariate analysis confirmed that CM expression was an independent prognostic factor, in contrast to phenotypic categorization (T-cell vs. null-cell group), which had no prognostic impact on disease-specific survival.
  • [MeSH-major] Granzymes / metabolism. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Poly(A)-Binding Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Hodgkin Disease / pathology. Humans. Lymphocytes, Null / pathology. Male. Middle Aged. Phenotype. Predictive Value of Tests. Prognosis. Reed-Sternberg Cells / pathology. Survival Analysis. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Histopathology. 2007 Jun;50(7):962
  • (PMID = 17493234.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human; EC 3.4.21.- / Granzymes
  •  go-up   go-down


23. Ferenczi K, Summers P, Aubert P, Cooper B, Meyerson H, Cooper KD, Honda K: A case of CD30+ nasal natural killer/T-cell lymphoma. Am J Dermatopathol; 2008 Dec;30(6):567-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of CD30+ nasal natural killer/T-cell lymphoma.
  • Extranodal nasal natural killer (NK)/T-cell lymphoma is a very rare lymphoma characterized by strong association with Epstein-Barr virus infection, very aggressive clinical behavior, and poor prognosis.
  • CD30 expression, a phenotype characteristic of anaplastic large-cell lymphomas, is not a typical feature of nasal NK/T-cell lymphomas.
  • A skin biopsy revealed an atypical angiocentric mononuclear cell infiltrate.
  • Strong CD30 and CD3e immunoreactivities were noted in large atypical mononuclear cells within the infiltrate initially suggestive of a CD30+ T-cell lymphoma.
  • Further studies revealed that the cells were CD56+, T-cell-restricted intracellular antigen-1+, and contained Epstein-Barr virus sequences consistent with a nasal-type NK/T-cell lymphoma.
  • High titers of Epstein-Barr virus in the blood, evidence of sinonasal disease, and absence of a T-cell receptor gene rearrangement were additional features consistent with the diagnosis.
  • This case represents an example of nasal-type NK/T-cell lymphoma with expression of CD30.
  • When presenting in the skin, the phenotypic and morphologic features of this lymphoma may lead to an erroneous diagnosis of a CD30+ large-T-cell lymphoma.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, T-Cell, Cutaneous / diagnosis. Natural Killer T-Cells / immunology. Natural Killer T-Cells / pathology. Nose Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunophenotyping. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033930.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


24. Goteri G, Simonetti O, Rupoli S, Piccinini G, Rubini C, Stramazzotti D, Fazioli F, Capomagi C, Leoni P, Offidani AM, Lo Muzio L: Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study. Br J Dermatol; 2007 Jul;157(1):41-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study.
  • BACKGROUND: Cutaneous CD30+ lymphoproliferative disorders (LPDs) are a spectrum of disease associated with a favourable prognosis.
  • Systemic anaplastic large cell lymphoma (ALCL), although morphologically and phenotypically similar, differs in clinical presentation and has a less favourable biological behaviour.
  • Dysregulation of apoptosis, the process regulating cell population by programmed death, can explain the differences among these disorders.
  • OBJECTIVES: We investigated the expression of two inhibitors of apoptosis, survivin and Bcl-2 protein, in serial skin lesion samples from CD30+ LPDs compared with systemic ALCL.
  • METHODS: Immunohistochemical analysis with antibodies against anaplastic lymphoma kinase (ALK)-1 protein, survivin and Bcl-2 protein was performed in 10 cutaneous CD30+ LPDs (five lymphomatoid papulosis, five ALCL) and 18 systemic ALCLs.
  • RESULTS: Cutaneous CD30+ LPDs shared a heterogeneous expression of cytoplasmic survivin with all systemic ALCLs, and of Bcl-2 with systemic ALK- ALCLs; however, they differ from systemic ALK- ALCLs because they lack nuclear survivin (P = 0.045), and from systemic ALK+ ALCLs by a higher expression of Bcl-2 (P = 0.045) and a lack of ALK-1.
  • Overall, coexpression of Bcl-2 and nuclear survivin in CD30+ LPDs was associated with a less favourable disease survival.
  • CONCLUSIONS: The different patterns of expression of Bcl-2 and survivin in CD30+ LPDs might have an impact on their different biological and clinical behaviour.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoproliferative Disorders / diagnosis. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cysteine Proteinase Inhibitors / pharmacology. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Inhibitor of Apoptosis Proteins. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Skin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Dermatol. 2007 Aug;157(2):431. Lomuzio, L [corrected to Lo Muzio, L]
  • (PMID = 17484779.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


25. Werner B, Massone C, Kerl H, Cerroni L: Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol; 2008 Dec;35(12):1100-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.
  • BACKGROUND: Cutaneous infectious and inflammatory diseases may contain a significant number of CD30-positive cells, thus mimicking lymphomatoid papulosis (LyP) or anaplastic large cell lymphoma.
  • METHODS: We reviewed our cases of non-neoplastic skin conditions with large, CD30-positive cells and searched the literature for similar cases.
  • CD30-positive cells were often arranged in clusters and revealed both Golgi and membrane positivity, similar to what was observed in LyP and CD30+ anaplastic large T-cell lymphoma.
  • CONCLUSIONS: Analysis of our data and of those published in the literature shows that viruses and drugs are the most common cause for occurrence of large CD30-positive cells in cutaneous pseudolymphomatous infiltrates.
  • Arrangement of these large, CD30-positive cells in small clusters is not unique to cutaneous CD30-positive lymphomas, and in many cases a precise diagnosis can be made only upon accurate clinicopathological correlation or using ancillary methods such as polymerase chain reaction analysis for viral DNA.
  • [MeSH-major] Antigens, CD30 / metabolism. Skin Diseases / metabolism. Skin Diseases / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions / metabolism. Drug-Related Side Effects and Adverse Reactions / pathology. Female. Humans. Infant. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology. Male. Middle Aged. Skin Neoplasms / pathology. Virus Diseases / metabolism. Virus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616762.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N02-CO-41101
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


26. Kong YY, Dai B, Kong JC, Lu HF, Shi DR: [Cutaneous anaplastic large cell lymphoma: clinicopathologic, immunohistochemical and prognostic study of 44 cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):230-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous anaplastic large cell lymphoma: clinicopathologic, immunohistochemical and prognostic study of 44 cases].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and prognosis of primary cutaneous anaplastic large cell lymphoma (CALCL).
  • Histologically, 31 cases were classified as common variant, 6 cases as small cell variant and 7 cases as neutrophil/eosinophil-rich variant.
  • Immunohistochemical study showed that the rates of expression of CD30, CD45, CD45RO, CD43, CD3, cytotoxic protein and epithelial membrane antigen were 100% (44/44), 91.2% (31/34), 82.6% (19/23), 94.7% (18/19), 70.0% (28/40), 73.3% (22/30) and 31.8% (7/22), respectively.
  • CONCLUSIONS: CALCL is a form of low-grade primary cutaneous T-cell lymphoma with a wide spectrum of clinicopathologic pattern.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunophenotyping. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654120.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


27. Chim CS, Ho J, Ooi GC, Choy C, Liang R: Primary anaplastic large cell lymphoma of the pancreas. Leuk Lymphoma; 2005 Mar;46(3):457-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic large cell lymphoma of the pancreas.
  • She was scheduled for a Whipple's operation and the intra-operative frozen section showed anaplastic carcinoma.
  • The proper diagnosis was only derived later with CD30 immunohistochemical study.
  • This carries important implications on the management, as radical surgery is indicated in resectable carcinoma but not for a chemosensitive lymphoma.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Female. Humans. Prednisolone / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use


28. Roden AC, Macon WR, Keeney GL, Myers JL, Feldman AL, Dogan A: Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol; 2008 Apr;21(4):455-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder.
  • Non-Hodgkin lymphomas of the breast are rare, encompassing approximately 0.04-0.5% of all malignant breast tumors, and the vast majority are B-cell lymphomas.
  • In contrast, lymphomas of T-cell phenotype have been rarely reported and some of these have been in close proximity to a breast implant.
  • In our consultation practice, we have identified four patients with primary T-cell anaplastic large-cell lymphoma presenting adjacent to silicone or saline breast implants.
  • In all patients, the neoplastic cells had a T-cell phenotype, expressed CD30, cytotoxic granule-associated proteins, EMA and clusterin, and were anaplastic lymphoma kinase-1-negative.
  • Clonal T-cell receptor gamma-chain gene rearrangements were identified in three patients.
  • Although the follow-up time was relatively short, our series and other reported cases suggest that primary anaplastic large-cell lymphoma adjacent to breast implants is an indolent T-cell lymphoproliferative disorder.
  • [MeSH-major] Breast Implants / adverse effects. Breast Neoplasms / etiology. Lymphoma, Large-Cell, Anaplastic / etiology. Seroma / etiology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Immunophenotyping. Mastectomy. Middle Aged


29. Vinogradova IuE, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Gorgidze LA, Ryzhikova NA, Valiev TT, Giliazitdinova EA, Dzhulakian UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremenetskaia AM, Kravchenko SK, Vorob'ev AI: [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas]. Ter Arkh; 2008;80(7):33-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
  • AIM: To compare efficacy of NHL-BFM-90 and CHOP-like courses in the treatment of anaplastic large cell lymphoma (ALCL).
  • The diagnosis was made basing on the findings of clinical, device, morphological, immunohistochemical and molecular-genetic examinations with application of a panel of monoclonal antibodies to CD30, ALK, CD3, CD4, CDS, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA, Ki-67.
  • 14 cases of 22 were negative by kinase of anaplastic lymphocytes (ALK-) and 8 were positive (ALK+).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Adult. Asparaginase / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction / methods. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763592.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; BEACOPP protocol; CHOP protocol; MACOP-B protocol; PVDA protocol
  •  go-up   go-down


30. Balachandran I, Walker JW Jr, Broman J: Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. Diagn Cytopathol; 2010 Mar;38(3):213-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review.
  • Epstein-Barr virus (EBV) related non-Hodgkin's lymphomas of B-cell type is more common than those of T-cell origin.
  • CD30 positive Anaplastic Large Cell Lymphoma (ALCL) is a Non-Hodgkin's lymphoma (B or T cell type) that accounts for a small percentage of PTLD's.
  • ALCL of T-cell type are a spectrum of disease ranging from primary cutaneous to systemic nodal ALCL.
  • The systemic nodal ALCL is further subdivided into anaplastic lymphoma kinase-1 (ALK-1) positive or negative.
  • We present an unusual manifestation of ALK-1 negative CD30 positive ALCL in a post renal transplant patient in FNA cytology with all supportive adjuvant studies and differential diagnoses and review the cytology literature on this topic.
  • [MeSH-major] Antigens, CD30 / analysis. Kidney Transplantation / adverse effects. Lymphoma, Large-Cell, Anaplastic / pathology. Mediastinal Neoplasms / pathology. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma / diagnosis. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunocompromised Host. Immunohistochemistry. Male. Melanoma / diagnosis. Postoperative Complications. Prednisone / therapeutic use. Receptor Protein-Tyrosine Kinases. Remission Induction. Seminoma / diagnosis. Seminoma / secondary. Testicular Neoplasms / diagnosis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19774614.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


31. Klapper W, Böhm M, Siebert R, Lennert K: Morphological variability of lymphohistiocytic variant of anaplastic large cell lymphoma (former lymphohistiocytic lymphoma according to the Kiel classification). Virchows Arch; 2008 Jun;452(6):599-605
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological variability of lymphohistiocytic variant of anaplastic large cell lymphoma (former lymphohistiocytic lymphoma according to the Kiel classification).
  • According to the WHO classification, anaplastic large cell lymphoma (ALCL) is a distinct T-cell lymphoma entity with a number of morphological variants.
  • The characteristic feature of lymphohistiocytic variant of ALCL according to the WHO classification is the abundance of histiocytes that exceed and mask the tumour cell population.
  • In the current, study we reanalysed a historical series of 17 lymphomas, diagnosed as lymphohistiocytic lymphoma according to the criteria of the Kiel classification, with the presence of large purple macrophages (LPM) as the decisive finding for diagnosing this lymphoma subtype.
  • Although all cases in our cohort matched the criteria of ALCL according to the WHO, in 30% of the cases, the total amount of macrophages did not exceed the number of CD30-positive tumour cells.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / analysis. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD30 / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Child. Child, Preschool. Cohort Studies. Female. Humans. Macrophages / pathology. Male. Mitosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Aug 15;96(4):1605-7 [10942417.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Blood. 2007 Jul 15;110(2):670-7 [17392503.001]
  • [Cites] Haematologica. 2006 Jan;91(1):48-55 [16434370.001]
  • [Cites] Am J Pathol. 1997 Apr;150(4):1207-11 [9094977.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):859-68 [8394652.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2939-53 [15583856.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Histopathology. 1990 Apr;16(4):383-91 [2163351.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3358-60 [15297316.001]
  • (PMID = 18478258.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


32. Weinberg OK, Seo K, Arber DA: Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol; 2008 Sep;39(9):1331-40
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?
  • The frequency of bone marrow involvement in anaplastic large cell lymphoma has been reported with great variation.
  • A prior study found that anaplastic large cell lymphoma involvement of bone marrow was often not evident on routine stains and advocated using immunohistochemical studies.
  • We evaluated 70 bone marrow biopsies from 41 patients with anaplastic large cell lymphoma and found 10 morphologically involved cases (14% of all biopsies, 22% of all patients).
  • In most cases (9/10 biopsies), the involvement of the bone marrow by anaplastic large cell lymphoma was massive and, thus, was evident on the hematoxylin and eosin section.
  • To determine if the hematoxylin and eosin evaluation missed bone marrow involvement, we used a panel of antibodies including CD30, ALK-1, epithelial membrane antigen, and granzyme.
  • Only the 10 morphologically involved cases showed anaplastic large cell lymphoma cells with distinct CD30 expression.
  • Other stains highlighted only a subset of the CD30-positive cases.
  • Overall, marrow involvement in anaplastic large cell lymphoma was relatively uncommon, and when present, it was identified on hematoxylin and eosin sections.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30 / immunology. Child. Child, Preschool. Clone Cells / pathology. Eosine Yellowish-(YS). Female. Hematoxylin. Humans. Immunohistochemistry. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602674.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


33. Bohling SD, Jenson SD, Crockett DK, Schumacher JA, Elenitoba-Johnson KS, Lim MS: Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma. Leuk Res; 2008 Mar;32(3):383-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
  • Anaplastic large cell lymphoma (ALCL) comprises a group of non-Hodgkin lymphomas characterized by the expression of the CD30/Ki-1 antigen.
  • A subset of ALCL is characterized by chromosomal translocations involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2.
  • These deregulated genes are involved in diverse cellular functions, such as cell cycle regulation, apoptosis, proliferation, and adhesion.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics. Tropomyosin / genetics
  • [MeSH-minor] Adult. Child. Gene Expression Profiling. Humans. Male. Oligonucleotide Array Sequence Analysis. Receptor Protein-Tyrosine Kinases. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17720243.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / TPM3 protein, human; 0 / Tropomyosin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


34. Gualco G, Chioato L, Weiss LM, Harrington WJ Jr, Bacchi CE: Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol; 2009 Jul;132(1):28-33
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children.
  • Anaplastic large cell lymphoma (ALCL) is recognized as 2 distinct diseases: anaplastic lymphoma kinase (ALK)+ ALCL and ALK- ALCL.
  • Human T-cell lymphotropic virus (HTLV-1) is linked to the development of adult T-cell leukemia/lymphoma (ATLL), which frequently expresses CD25.
  • Some cases of adult HTLV-1-related lymphomas have characteristics of ALCL but are considered CD30+ ATLL subtypes.
  • All cases corresponded to the common histologic ALCL type and were CD30+ in virtually all neoplastic cells.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2003 Aug;112(2):e136-42 [12897319.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5587-94 [15328201.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Leukemia. 1994 Mar;8(3):507-9 [8127156.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):614-9 [7774890.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):683-9 [9502410.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1505-10 [18620733.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 May 1;21(1):65-71 [10235516.001]
  • [Cites] Blood. 1999 May 1;93(9):3088-95 [10216106.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4624-33 [15735688.001]
  • [Cites] J Virol. 2005 Sep;79(18):11925-34 [16140768.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):575-83 [16410787.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):690-2 [16410788.001]
  • [Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]
  • [Cites] J Pediatr (Rio J). 2006 Nov-Dec;82(6):411-20 [17171202.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):875-82 [17951212.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:285-96 [18024642.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):784-7 [18022899.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1830-5 [11920547.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):117-33 [12670470.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]
  • (PMID = 19864230.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / R01 CA121935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS125676; NLM/ PMC2771325
  •  go-up   go-down


35. Chuang SS, Hsieh YC, Ye H, Hwang WS: Lymphohistiocytic anaplastic large cell lymphoma involving skin: a diagnostic challenge. Pathol Res Pract; 2009;205(4):283-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphohistiocytic anaplastic large cell lymphoma involving skin: a diagnostic challenge.
  • Systemic anaplastic large cell lymphoma (ALCL) involving the skin should be differentiated from primary cutaneous CD30-positive T-cell lymphoproliferative disorders.
  • Biopsy of the cervical lymph node showed LH-ALCL with null cell phenotype.
  • Microscopically, the cutaneous lesion was located predominately around the hair follicle, with numerous reactive histiocytes and scanty medium-sized lymphoma cells expressing CD30 and anaplastic lymphoma kinase (ALK) protein.
  • In addition to B-and T-cell markers, (dermato) pathologists must be aware of this entity in cutaneous lymphohistiocytic proliferations and perform immunostaining for CD30 and ALK to reach a correct diagnosis.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Gene Rearrangement. Histiocytes / pathology. Humans. In Situ Hybridization, Fluorescence. Male. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091487.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


36. Yang HB, Li J, Shen T: Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review. Acta Haematol; 2007;118(3):188-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review.
  • To our knowledge, only eleven cases of primary anaplastic large cell lymphoma (ALCL) of the lung have previously been reported.
  • CD30-positive ALCL was demonstrated by histopathological studies of the lung tissue.
  • Primary pulmonary lymphoma is a great challenge for pneumologists since the clinical presentations and radiological findings are nonspecific.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD30 / metabolism. Asian Continental Ancestry Group. Biopsy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17934256.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD30; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 15
  •  go-up   go-down


37. Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G, Delsol G, Brousset P: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol; 2009 Sep 1;27(25):4211-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.
  • PURPOSE: Anaplastic lymphoma kinase (ALK) -positive diffuse large B-cell lymphoma (DLBCL) is a rare variant of DLBCL that has been described only in small case reports.
  • All patients expressed ALK fusion proteins, but virtually all were CD30 and CD20 negative.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / enzymology. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD20 / analysis. Antigens, CD30 / analysis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Oncogene Proteins, Fusion / analysis. Prednisone / administration & dosage. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2010 Jan 1;28(1):182
  • (PMID = 19636007.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / oncoprotein CLTCL-ALK; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


38. Wang WY, Ma ZG, Li GD, Liu WP, Zhong L, Wang Y, Li JM, Li L, Jiang W, Tang Y, Liao DY: [Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein: clinicopathologic and immunohistochemical study of 5 cases]. Zhonghua Bing Li Xue Za Zhi; 2006 Sep;35(9):529-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein: clinicopathologic and immunohistochemical study of 5 cases].
  • OBJECTIVE: To study the clinicopathologic features of diffuse large B-cell lymphoma (DLBCL) with expression of anaplastic lymphoma kinase (ALK) protein.
  • Only ALK-positive cases by EnVision technique were further analyzed by immunostaining for antigens including CD20, CD3, CD30, EMA, granzyme-B, TIA-1 and PC.
  • Morphologic subtypes included centroblastic 2, anaplastic 1, immunoblastic with plasmacytoid differentiation 1 and plasmablastic 1.
  • Immunohistochemically, 4 cases were CD20 positive (including 2 centroblastic, 1 anaplastic and 1 immunoblastic cases).
  • As for ALK protein staining, a mixed membranous and cytoplasmic (1 immunoblastic case), granular cytoplasmic (2 centroblastic and 1 anaplastic cases) and mixed nuclear and cytoplasmic (1 plasmablastic case) patterns were observed.
  • CONCLUSIONS: Expression of ALK protein is a rare phenomenon in DLBCL and can be seen in centroblastic, anaplastic, immunoblastic and plasmablastic subtypes.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD20 / metabolism. Female. Follow-Up Studies. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin kappa-Chains / metabolism. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134546.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin kappa-Chains; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


39. Vassallo J, Lamant L, Brugieres L, Gaillard F, Campo E, Brousset P, Delsol G: ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases. Am J Surg Pathol; 2006 Feb;30(2):223-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large cell lymphoma mimicking nodular sclerosis Hodgkin's lymphoma: report of 10 cases.
  • Anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) are recognized as biologically distinct entities.
  • Neoplastic cells were positive for CD30 (10 of 10 cases), ALK protein (10 of 10 cases), epithelial membrane antigen (EMA) (9 of 9 cases), CD43 (6 of 9 cases), and perforin (8 of 8 cases), but negative for CD15 (10 of 10 cases), CD20 (10 of 10 cases), Pax5/BSAP (6 of 6 cases), and EBV (8 of 8 cases).
  • [MeSH-major] Biomarkers, Tumor / analysis. Hodgkin Disease / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged, 80 and over. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Receptor Protein-Tyrosine Kinases. Sclerosis / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434897.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


40. Wang TT, Wang L, Tang ZR, Cheng JR, Li W, Li FY, Wang WY, Li GD: [Primary cutaneous anaplastic large cell lymphoma: a clinicopathologic analysis of 8 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):749-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutaneous anaplastic large cell lymphoma: a clinicopathologic analysis of 8 cases].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and prognosis of primary cutaneous anaplastic large cell lymphoma (C-ALCL).
  • Histologically, the lymphoma cells infiltrated the dermis and subcutis in a sheet-like pattern.
  • They were of large size and showed conspicuous nuclear atypia.
  • Immunohistochemical study showed that more than 75% of the lymphoma cells were positive for CD30.
  • All cases expressed one to three T cell markers (CD3, CD5 or CD45RO) and cytotoxic granule-associated antigens (TIA-1, granzyme B or perforin).
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD45 / metabolism. Antigens, CD5 / metabolism. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunophenotyping. In Situ Hybridization. Male. Middle Aged. Prognosis. RNA, Viral / metabolism. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079014.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD5; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


41. Shi Y, Chen G, Zhou XG, Gong LP, Yu R, Zheng YY, Xie JL, Jin Y: [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):235-9
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
  • OBJECTIVE: To study the clinicopathologic features of 66 cases of primary systemic anaplastic large cell lymphoma (ALCL), with emphasis on the differences between ALK-positive and ALK-negative cases.
  • Immunohistochemical study for CD30, ALK protein, epithelial membrane antigen, CD2, CD3, granzyme B and TIA-1 was carried out.
  • Small cell variant and sarcomatoid subtype were found only in few cases (3 cases and 2 cases, respectively).On the other hand, common variant (17 cases) constituted the majority of ALK-negative ALCL.
  • Immunohistochemical study showed that ALK-positive ALCL always expressed CD30 and epithelial membrane antigen.
  • ALK-positive ALCL more often expressed epithelial membrane antigen (100% versus 72%; P < 0.05) but less so for T-cell markers (including CD2, CD3, CD43 and CD45RO).
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antigens, CD30 / metabolism. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Gene Deletion. Humans. Male. Malignant Hyperthermia / etiology. Middle Aged. Mucin-1 / metabolism. Neoplasm Recurrence, Local. Receptor Protein-Tyrosine Kinases. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654121.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


42. Saikia UN, Sharma N, Duseja A, Bhalla A, Joshi K: Anaplastic large cell lymphoma presenting as acute liver failure: A report of two cases with review of literature. Ann Hepatol; 2010 Oct-Dec;9(4):457-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma presenting as acute liver failure: A report of two cases with review of literature.
  • Primary hepatic anaplastic large cell lymphoma (ALCL) of the liver is a rare entity.
  • We present here two cases of primary hepatic anaplastic large cell lymphoma (ALCL) of the null-cell type.
  • These cells were positive for CD30, negative for CD3, CD20 and EMA, and diagnosed as ALCL of the null-cell type.
  • [MeSH-major] Liver Failure, Acute / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Bilirubin / blood. Biopsy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Liver / enzymology. Liver / pathology. Male


43. Lu Y, Zhao X, Wang E, Chen W, Huang Q: ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". Leuk Res; 2010 Apr;34(4):475-82
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase".
  • CD30-positive anaplastic large cell lymphoma (ALCL) is a distinctive malignant large cell lymphoma of T-cell lineage, often presenting in lymph node or extranodal sites.
  • ALCL cases with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase" are extremely rare and the most of those cases reported are anaplastic large cell lymphoma kinase (ALK) positive ALCL in childhood population.
  • Here we report four adult cases of ALK-negative ALCL with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase".
  • Circulating large lymphoma cells varied from 20 to 80% in peripheral blood and bone marrow biopsy showed various nodular or interstitial infiltrates.
  • By reviewing the clinicopathologic data of previously reported ALCL cases with extensive bone marrow and peripheral blood involvement, there appears to be of large variations in regard to the patient's age, morphologic variants, immunophenotypic or genotypic characteristics of the disease.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19695703.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


44. Kesler MV, Paranjape GS, Asplund SL, McKenna RW, Jamal S, Kroft SH: Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases. Am J Clin Pathol; 2007 Aug;128(2):314-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases.
  • We report our experience with flow cytometric (FC) analysis of 29 cases of anaplastic large cell lymphoma (ALCL).
  • Of 21 cases, 13 were anaplastic lymphoma kinase (ALK)+, all of which were CD4+, vs 5 of 8 ALK - cases (P = .042).
  • [MeSH-major] Antigens, CD / analysis. Flow Cytometry / methods. Lymphoma, Large B-Cell, Diffuse / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Child. Child, Preschool. Female. Humans. Light. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Scattering, Radiation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638668.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


45. Papalas JA, Van Mater D, Wang E: Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young. Am J Dermatopathol; 2010 Dec;32(8):821-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young.
  • Cutaneous anaplastic large-cell lymphoma belongs to the class of primary cutaneous CD30-positive lymphoproliferative disorders.
  • We describe 2 cases (one which clinically presented as cellulitis, and another arising in a patient with Hodgkin lymphoma) and review the clinicopathologic features of cases reported in the literature.
  • Immunophenotypically, the anaplastic large cells demonstrate loss of pan-T cell antigens, CD2, CD3, CD5, and CD7, with 65% of cases expressing CD4 and 29% of cases expressing CD8.
  • In the clinical context of a progressive ulcerating lesion in younger or immunocompromized patients, it is important for the pathologist when presented with a skin specimen demonstrating a neutrophil-rich inflammatory background to include the pyogenic variant of anaplastic large-cell lymphoma.
  • We hope to increase awareness of this rare CD30-positive lymphoproliferative disorder subtype by better defining the clinical spectrum in which this entity can present.
  • [MeSH-major] Immunocompromised Host. Lymphoma, Primary Cutaneous Anaplastic Large Cell / immunology. Neutrophils / immunology. Skin / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Young Adult


46. Wong AK, Lopategui J, Clancy S, Kulber D, Bose S: Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature. Am J Surg Pathol; 2008 Aug;32(8):1265-8
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature.
  • Primary lymphomas of the breast are rare and predominately of B-cell phenotype.
  • Anaplastic large cell lymphoma is a T-cell lymphoma that accounts for only 3% of all non-Hodgkin lymphomas.
  • We present a rare case of primary anaplastic large cell lymphoma of the breast in association with a silicone breast implant capsule in a healthy 40-year-old woman.
  • Histology, immunohistochemistry, and T-cell gene rearrangement studies were supportive of a CD 30-positive ALK-1 negative anaplastic large cell lymphoma.
  • This case represents the 14th reported case of primary breast lymphoma in association with breast prosthesis.
  • Of interest is that 11 of these cases were T-cell lymphomas with 8 specifically of the CD30-positive anaplastic large cell lymphoma type.
  • [MeSH-major] Breast Implantation. Breast Implants / adverse effects. Breast Neoplasms / etiology. Lymphoma, Large-Cell, Anaplastic / etiology. Silicone Gels
  • [MeSH-minor] Adult. Antigens, CD30 / analysis. Device Removal. Female. Gene Expression Regulation, Neoplastic. Gene Rearrangement, T-Lymphocyte. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Prosthesis Design

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594466.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Immunoglobulin Heavy Chains; 0 / Silicone Gels
  • [Number-of-references] 24
  •  go-up   go-down


47. Murphy AJ, O'Neill P, O'Brien F, Enright H, Jeffers M, Thornhill JA, Loftus BM: Anaplastic large cell lymphoma: a unique presentation with urinary bladder involvement: a case report. Int J Surg Pathol; 2005 Oct;13(4):369-73
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: a unique presentation with urinary bladder involvement: a case report.
  • Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma composed of large pleomorphic CD30-positive cells.
  • Bladder biopsies showed diffuse infiltration of the lamina propria by large pleomorphic cells, with preservation of the overlying urothelium.
  • Immunohistochemistry demonstrated cell membrane and Golgi region staining for CD30 and epithelial membrane antigen.
  • [MeSH-major] Carcinoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD30 / analysis. Cell Membrane / immunology. Diagnosis, Differential. Golgi Apparatus / immunology. Humans. Immunohistochemistry. Male. Mucin-1 / analysis. Urothelium / metabolism. Urothelium / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273198.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Mucin-1
  •  go-up   go-down


48. Park SJ, Kim S, Lee DH, Jeong YP, Bae Y, Han EM, Huh J, Suh C: Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center. Yonsei Med J; 2008 Aug 30;49(4):601-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center.
  • PURPOSE: Anaplastic large cell lymphoma (ALCL), a CD30+ T-cell non-Hodgkin's lymphoma, represents only 2-8% of lymphoma overall.
  • PATIENTS AND METHODS: We retrospectively reviewed the medical records of 36 adult patients diagnosed with primary systemic ALCL at Asan Medical Center from February 1995 through June 2006.
  • Univariate analysis showed that performance status (p = 0.035), international prognostic index (IPI) (p = 0.025), and age-adjusted IPI (p = 0.034) were significant prognostic factors for OS, whereas anaplastic lymphoma kinase (ALK) expression did not affect OS (p = 0.483).
  • [MeSH-major] Hospitals. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):633-8 [16891805.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):129-50 [11754390.001]
  • [Cites] J Pathol. 2003 May;200(1):4-15 [12692835.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1727-31 [14692525.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):943-9 [7683712.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 Jan 1;85(1):1-14 [7803786.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):955-62 [8622045.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Haematologica. 1999 May;84(5):425-30 [10329921.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Histopathology. 2006 Apr;48(5):481-504 [16623775.001]
  • [Cites] Hematol Oncol. 1999 Dec;17(4):137-48 [10725869.001]
  • (PMID = 18729302.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2615286
  •  go-up   go-down


49. Pant V, Jambhekar NA, Madur B, Shet TM, Agarwal M, Puri A, Gujral S, Banavali M, Arora B: Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases. Indian J Pathol Microbiol; 2007 Apr;50(2):303-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases.
  • This study highlights the rare presentation of anaplastic large cell lymphoma as primary bone and soft tissue tumour.
  • Clinical impression was non Hodgkin's lymphoma in 4 cases, sarcoma in 6 (osteosarcoma-2, Ewing's/primitive neuroectodermal tumour-1, and sarcoma NOS-3), and tuberculosis of thoracic spine in 1 and the last case involving the rib had a differential diagnosis of tuberculosis and NHL.
  • Immunohistochemically all tumours were CD30 positive and 8 of 9 cases (88.9%) showed ALK-1 positivity.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Activin Receptors, Type II / metabolism. Adolescent. Adult. Antigens, CD30 / metabolism. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male


50. Kong YY, Dai B, Kong JC, Lu HF, Shi DR: Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases. Histopathology; 2009 Aug;55(2):189-96
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases.
  • AIMS: To elucidate the clinicopathological, immunophenotypic and molecular features of neutrophil/eosinophil-rich primary cutaneous anaplastic large cell lymphoma (CALCL), and to emphasize the cutaneous manifestations, differential diagnosis and prognosis of this peculiar entity.
  • Histologically, cohesive sheets or small clusters of neoplastic cells were admixed with large numbers of neutrophils and/or eosinophils, representing 10-40% of cells per high-power field.
  • All nine cases showed T-cell phenotypes.
  • CONCLUSIONS: Neutrophil/eosinophil-rich CALCL should be differentiated from various infectious and non-infectious diseases, especially from non-neoplastic cutaneous CD30+ infiltrates rich in neutrophils and eosinophils.
  • [MeSH-major] Eosinophils / pathology. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Neutrophils / pathology. Skin / pathology. Skin Diseases / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD30 / metabolism. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Follow-Up Studies. Gene Rearrangement, T-Lymphocyte. Humans. Immunophenotyping. Leukemic Infiltration / immunology. Leukemic Infiltration / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Skin Neoplasms / diagnosis. Skin Neoplasms / immunology. Skin Neoplasms / metabolism. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694826.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


51. Miranda RN, Lin L, Talwalkar SS, Manning JT, Medeiros LJ: Anaplastic large cell lymphoma involving the breast: a clinicopathologic study of 6 cases and review of the literature. Arch Pathol Lab Med; 2009 Sep;133(9):1383-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma involving the breast: a clinicopathologic study of 6 cases and review of the literature.
  • CONTEXT: Lymphomas involving the breast are rare, and most cases are of B-cell lineage; T-cell neoplasms represent less than 10% of all breast lymphomas.
  • OBJECTIVE: To define the clinicopathologic spectrum of anaplastic large cell lymphomas (ALCLs) involving the breast.
  • There were 4 anaplastic lymphoma kinase- negative (ALK(-)) ALCL cases; 3 of these neoplasms developed around breast implants.
  • Histologically, all neoplasms were composed of large anaplastic cells that were uniformly CD30(+) and expressed markers of T-cell lineage.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD30 / metabolism. Biomarkers, Tumor / metabolism. Breast Implantation. Combined Modality Therapy. DNA, Neoplasm / analysis. Fatal Outcome. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722744.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


52. Bobos M, Kotoula V, Kaloutsi V, Karayannopoulou G, Papadimitriou CS, Kostopoulos I: Aberrant CCND1 copies and cyclin D1 mRNA expression do not result in the production of functional cyclin D1 protein in anaplastic large cell lymphoma. Histol Histopathol; 2009 08;24(8):1035-48
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CCND1 copies and cyclin D1 mRNA expression do not result in the production of functional cyclin D1 protein in anaplastic large cell lymphoma.
  • Scattered reports in the literature have shown that Cyclin D1 mRNA and protein may be expressed in anaplastic large cell lymphoma (ALCL).
  • Aberrant Cyclin D1 expression seems to promote proliferation in other types of lymphoma, while a growth promoting CCND1/TACSD1(TROP2) fusion product has also been described in tumors.
  • This change was specific for CD30+ neoplastic cells, as shown by double fluorescent staining.
  • [MeSH-major] Cyclin D1 / genetics. Gene Dosage. Lymphoma, Large-Cell, Anaplastic / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD30 / metabolism. Child. Chromosomes, Human, Pair 11 / genetics. Female. Fluorescein-5-isothiocyanate / metabolism. Fluorescent Dyes / metabolism. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Indoles / metabolism. Male. Middle Aged. Rhodamines / metabolism. Young Adult


53. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH: CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol; 2009 Dec;33(12):1860-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
  • The major differential diagnosis for a primary cutaneous T-cell lymphoproliferative disorder with CD30 (Ki-1) positivity includes primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, pagetoid reticulosis and transformed mycosis fungoides (MF).
  • Little is known, however, about CD30 expression in nontransformed MF, whether it simply reflects the proliferative fraction and if either CD30 staining or the proliferative fraction are of prognostic significance.
  • Therefore, 47 nontransformed MF biopsies were stained for CD30 and Ki-67.
  • All cases had at least rare dermal CD30-positive cells.
  • Higher percentages of dermal CD30 and Ki-67-positive cells were associated with a higher stage at diagnosis, and together with epidermal CD30, associated with a higher maximum stage.
  • The proportion of CD30 and Ki-67-positive cells did not correlate with each other.
  • Survivals were shorter if the dermal CD30 or epidermal or dermal Ki-67% were greater than the median (4.7%, 14%, 13%) and in patients of greater than or equal to 60 years of age or with a high stage.
  • Dermal Ki-67 as a continuous variable was an independent prognostic indicator (P<0.001), as were dermal Ki-67 (P=0.004) and dermal CD30 (P=0.027) when analyzed as dichotomous variables but not stage.
  • Therefore, CD30 expression is not restricted to transformed MF but higher levels of dermal CD30 expression and, even more so, dermal Ki-67 levels are independent adverse prognostic indicators.

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Apr 1;95(7):2212-8 [10733487.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1150-9 [9694702.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):625-36 [9711925.001]
  • [Cites] Dermatology. 1998;197(2):123-6 [9732159.001]
  • [Cites] Histopathology. 1998 Sep;33(3):240-7 [9777390.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3376-80 [9787176.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24 [10365922.001]
  • [Cites] Haematologica. 2005 Feb;90(2):200-6 [15710572.001]
  • [Cites] J Am Acad Dermatol. 2005 Jul;53(1):158-63 [15965442.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):575-83 [16410787.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):727-36 [16707374.001]
  • [Cites] J Am Acad Dermatol. 2006 Aug;55(2):276-84 [16844512.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):284-9 [17573879.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1713-22 [17540844.001]
  • [Cites] Prilozi. 2007 Jul;28(1):39-55 [17921917.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5):782-90 [17646032.001]
  • [Cites] J Dermatol Sci. 2008 Feb;49(2):125-32 [17826963.001]
  • [Cites] G Ital Dermatol Venereol. 2008 Feb;143(1):15-9 [18833048.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(4):881-6 [18644018.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3082-7 [18647960.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2081-90 [19021050.001]
  • [Cites] J Am Acad Dermatol. 2009 Feb;60(2):231-5 [19026464.001]
  • [Cites] J Clin Pathol. 2009 Feb;62(2):128-38 [18794197.001]
  • [Cites] Mod Pathol. 2000 May;13(5):502-10 [10824921.001]
  • [Cites] Am J Dermatopathol. 2000 Jun;22(3):212-6 [10871063.001]
  • [Cites] Blood. 2001 Feb 1;97(3):624-30 [11157477.001]
  • [Cites] J Cutan Pathol. 2001 Aug;28(7):356-62 [11437941.001]
  • [Cites] Arch Dermatol. 2002 Feb;138(2):199-203 [11843640.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):11-20 [12270057.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3369-73 [12384439.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):857-66 [12873880.001]
  • [Cites] Diagn Mol Pathol. 2003 Sep;12(3):142-50 [12960696.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):725-8 [445521.001]
  • [Cites] Am J Pathol. 1988 Aug;132(2):265-77 [3261136.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Am J Pathol. 1990 Feb;136(2):261-6 [1968314.001]
  • [Cites] Hematol Oncol. 1990 Jul-Aug;8(4):215-27 [2210690.001]
  • [Cites] Am J Pathol. 1990 Dec;137(6):1447-51 [2260631.001]
  • [Cites] J Dermatol. 1991 Mar;18(3):152-60 [1885849.001]
  • [Cites] J Cutan Pathol. 1995 Feb;22(1):11-7 [7751472.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1423-30 [7503364.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):487-91 [9066700.001]
  • [Cites] J Am Acad Dermatol. 1997 Jul;37(1):58-67 [9216524.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):281-5 [9234572.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2429-36 [9310494.001]
  • [Cites] Am J Dermatopathol. 1998 Feb;20(1):1-6 [9504661.001]
  • (PMID = 19898220.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / RR000056-440857; United States / NCRR NIH HHS / RR / UL1 RR024153; United States / NCRR NIH HHS / RR / M01 RR000056-440857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ NIHMS153861; NLM/ PMC3733448
  •  go-up   go-down


54. Kamstrup MR, Ralfkiaer E, Skovgaard GL, Gniadecki R: Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol; 2008 Apr;158(4):747-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders.
  • BACKGROUND: The central role of Notch signalling in T-cell development and oncogenesis raises the question of the importance of this pathway in cutaneous T-cell lymphomas.
  • OBJECTIVES: To investigate the pattern of expression of Notch and its ligands, Jagged and Delta, in skin samples of primary cutaneous CD30+ lymphoproliferative disorders.
  • METHODS: Immunohistochemistry of formalin-fixed, paraffin-embedded skin samples from 12 patients with lymphomatoid papulosis (LyP) and 11 patients with primary cutaneous anaplastic large cell lymphoma (ALCL).
  • A subpopulation of lymphoma cells was found to coexpress Notch1 and activated Akt kinase.
  • CONCLUSIONS: These results imply a potential role for the Notch signalling pathway in the pathogenesis of primary cutaneous CD30+ lymphoproliferative disorders and provide a rationale for the exploration of the activity of Notch antagonists in the therapy of these diseases.
  • [MeSH-major] Antigens, CD30 / metabolism. Calcium-Binding Proteins / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphomatoid Papulosis / immunology. Membrane Proteins / metabolism. Receptor, Notch1 / metabolism. Skin Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Ligands. Male. Middle Aged. Signal Transduction / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241263.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ligands; 0 / Membrane Proteins; 0 / Receptor, Notch1; 134324-36-0 / Serrate proteins
  •  go-up   go-down


55. Shimizu Y, Tanae K, Takahashi N, Kohri M, Arai E, Bessho M, Niitsu N: Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. Leuk Res; 2010 Feb;34(2):263-6
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature.
  • Primary cutaneous anaplastic large-cell lymphoma (C-ALCL) is a rare entity of lymphoma.
  • Histopathological examination of the skin biopsy specimens showed non-epidermotropic infiltrates with cohesive sheets of large tumor cells.
  • The tumor cells showed CD4-, CD8+, CD30+, CD56-, ALK-, TIA-1+, and granzyme B+.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Skin Ulcer / etiology
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19640585.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  •  go-up   go-down


56. Benner MF, Willemze R: Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients. Br J Dermatol; 2008 Nov;159(5):1148-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients.
  • BACKGROUND: According to criteria of the World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas a diagnosis of primary cutaneous CD30-positive anaplastic large cell lymphoma (C-ALCL) should be made only when systemic localizations have been excluded by adequate staging procedures, including a bone marrow biopsy.
  • METHODS: All patients presenting with skin lesions with histological and immunophenotypical features of an ALCL were retrieved from the database of the Dutch Cutaneous Lymphoma Group.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782320.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Kodama K, Hokama M, Kawaguchi K, Tanaka Y, Hongo K: Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature. Neuropathology; 2009 Apr;29(2):166-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature.
  • Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma composed of CD30-positive cells.
  • Anaplastic lymphoma kinase (ALK) -1 positive ALCL frequently involves both lymph nodes and extranodal sites.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adolescent. Aged. Blotting, Southern. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564100.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  • [Number-of-references] 29
  •  go-up   go-down


58. Yamaguchi T, Ohshima K, Karube K, Kawano R, Nakayama J, Suzumiya J, Kikuchi M: Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol; 2006 May;154(5):904-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
  • BACKGROUND: Little is known about the mechanisms involved in skin-specific homing in CD30+ cutaneous lymphoproliferative disorders (CLPD).
  • Chemokine/chemokine receptor interactions have been implicated in the homing of lymphoma cells to various tissue sites.
  • OBJECTIVES: To investigate tissue samples from patients with CD30+ CLPD for the expression of the chemokine receptors CXCR3, CCR4 and CCR3 and their ligands MIG, TARC and RANTES.
  • METHODS: Tissue samples from patients with primary cutaneous anaplastic large cell lymphoma (PCALCL, n=12) and lymphomatoid papulosis (LyP, n=13) were studied by immunohistochemistry on paraffin-embedded sections.
  • Immunohistochemical analysis was also performed for CD20 (for B cells), CD45RO and CD3 (for T cells), CD30 and ALK-1.
  • A portion of each skin specimen was stored at -80 degrees C and later examined using monoclonal antibodies against CD2, CD3, CD4, CD5, CD8, CD15, CD19, CD20 and CD30.
  • RESULTS: CD30+ atypical lymphoid cells were frequently seen in PCALCL, and to a variable degree in LyP.
  • RANTES was strongly expressed by lymphoma cells in PCALCL (11 of 12: 92%), but was weak or sporadic in LyP (seven of 13: 54%).
  • [MeSH-major] Chemokines / metabolism. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphomatoid Papulosis / immunology. Receptors, Chemokine / metabolism. Skin Neoplasms / immunology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD30 / analysis. Chemokine CCL5 / metabolism. Chemokine CXCL9. Chemokines, CXC / metabolism. Child. Female. Humans. Ligands. Male. Middle Aged. Neoplasm Proteins / metabolism. Receptors, CCR3. Receptors, CXCR3

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634894.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CCR3 protein, human; 0 / CXCL9 protein, human; 0 / CXCR3 protein, human; 0 / Chemokine CCL5; 0 / Chemokine CXCL9; 0 / Chemokines; 0 / Chemokines, CXC; 0 / Ligands; 0 / Neoplasm Proteins; 0 / Receptors, CCR3; 0 / Receptors, CXCR3; 0 / Receptors, Chemokine
  •  go-up   go-down


59. Proca DM, De Renne L, Marsh WL Jr, Keyhani-Rofagha S: Anaplastic large cell lymphoma in a human immunodeficiency virus-positive patient with cytologic findings in bladder wash: a case report. Acta Cytol; 2008 Jan-Feb;52(1):83-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in a human immunodeficiency virus-positive patient with cytologic findings in bladder wash: a case report.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) (Ki-1/CD-30 positive) is an uncommon lymphoproliferative disorder that may be of T cell or null cell type.
  • The ALCL was CD30+ and null cell type, with negative CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD45, CD79a, ALK-1, granzyme B, cytokeratin (AE1/AE3), placental alkaline phosphatase (PLAP) and S-100.
  • CONCLUSION: This is a rare occurrence of ALCL (CD 30 positive, null cell type) in the urinary bladder in an HIV+ patient.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis. Urinary Bladder / pathology
  • [MeSH-minor] Adult. Humans. Male


60. Eckerle S, Brune V, Döring C, Tiacci E, Bohle V, Sundström C, Kodet R, Paulli M, Falini B, Klapper W, Chaubert AB, Willenbrock K, Metzler D, Bräuninger A, Küppers R, Hansmann ML: Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia; 2009 Nov;23(11):2129-38
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
  • Anaplastic large cell lymphoma (ALCL) is a main type of T-cell lymphomas and comprises three distinct entities: systemic anaplastic lymphoma kinase (ALK) positive, systemic ALK(-) and cutaneous ALK(-) ALCL (cALCL).
  • Little is known about their pathogenesis and their cellular origin, and morphological and immunophenotypical overlap exists between ALK(-) ALCL and classical Hodgkin lymphoma (cHL).
  • We conducted gene expression profiling of microdissected lymphoma cells of five ALK(+) and four ALK(-) systemic ALCL, seven cALCL and sixteen cHL, and of eight subsets of normal T and NK cells.
  • The analysis supports a derivation of ALCL from activated T cells, but the lymphoma cells acquired a gene expression pattern hampering an assignment to a CD4(+), CD8(+) or CD30(+) T-cell origin.
  • Indeed, ALCL display a down-modulation of many T-cell characteristic molecules.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Hodgkin Disease / genetics. Lymphoma, Large-Cell, Anaplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line. Female. Humans. Immunohistochemistry. Killer Cells, Natural / cytology. Killer Cells, Natural / physiology. Male. Microdissection. Middle Aged. NF-kappa B / metabolism. Phenotype. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. T-Lymphocytes / cytology. T-Lymphocytes / physiology. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657361.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


61. Magro CM, Weinerman DJ, Porcu PL, Morrison CD: Post-transplant EBV-negative anaplastic large-cell lymphoma with dual rearrangement: a propos of two cases and review of the literature. J Cutan Pathol; 2007 Dec;34 Suppl 1:1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant EBV-negative anaplastic large-cell lymphoma with dual rearrangement: a propos of two cases and review of the literature.
  • The vast majority of these lesions represent monomorphic B-cell lymphoproliferative disease.
  • Rarely, however, T-cell malignancies may emerge, the commonest being anaplastic large-cell lymphoma (ALCL).
  • The neoplastic cell populace was composed of CD4-positive cytotoxic T cells exhibiting CD30 positivity.
  • Striking and prominent clonally restricted infiltrates were identified whereby there was both a heavy chain and T-cell beta gene rearrangement.
  • CONCLUSION: T-cell-associated PTLD does not appear to be directly attributable to EBV infection.
  • Iatrogenic immune dysregulation may result in excessive T-cell proliferation to various antigenic stimuli, hence resembling other drug-associated cell lymphoproliferative conditions such as angioimmunoblastic lymphadenopathy.
  • The dual rearrangement may have some implications regarding the cell of origin.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics. Herpesvirus 4, Human / isolation & purification. Liver Transplantation / adverse effects. Lymphoma, Large-Cell, Anaplastic / pathology. Postoperative Complications. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. DNA, Neoplasm / analysis. Electrophoresis, Capillary. Fatal Outcome. Female. Humans. Immunocompromised Host. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Remission Induction


62. Aitova LG, Vinogradova IuE, Kaplanskaia IB, Lutsenko IN, Zvonkov EE, Momotiuk KS, Kravchenko SK, Kremenetskaia AM, Vorob'ev AI: [High-dose polychemotherapy of patients with poor-prognosis anaplastic T.0-large cell ALK+ lymphosarcoma]. Ter Arkh; 2009;81(7):53-7
Genetic Alliance. consumer health - Lymphosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose polychemotherapy of patients with poor-prognosis anaplastic T.0-large cell ALK+ lymphosarcoma].
  • AIM: To evaluate efficacy of the protocol NHL BFM-90 in the treatment of adult anaplastic large cell lymphosarcoma (ALCL) ALK+ and validity of addition of transplantation of autologous stem hemopoietic cells (ASHC) into first line treatment.
  • The diagnosis was made using morphological, histological, immunohistochemical methods with application of monoclonal antibodies to CD30, ALK, CD3, CD4, CD8, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Receptor Protein-Tyrosine Kinases. Remission Induction. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708574.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


63. Ishibashi M, Ohshima K, Chen KR: Folliculotropic mycosis fungoides with eosinophilia and CD30+ large-cell transformation: a case with a fatal outcome presenting with multifocal lesions and leonine facies. Clin Exp Dermatol; 2010 Jun;35(4):e133-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folliculotropic mycosis fungoides with eosinophilia and CD30+ large-cell transformation: a case with a fatal outcome presenting with multifocal lesions and leonine facies.
  • Eosinophilia is recognized as a poor prognostic factor in patients with cutaneous T-cell lymphoma (CTCL).
  • On histopathological examination, nodular infiltration of large CD30+ large cells was seen.
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / pathology. Male

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925483.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Park SR, Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS: Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. J Korean Med Sci; 2006 Aug;21(4):633-8
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
  • Despite advances in the characterization of anaplastic large cell lymphoma (ALCL), little data is available on Asian patients.
  • The staining results for anaplastic lymphoma kinase were positive in 6 (33%) of 18 cases available.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD30 / analysis. Female. Humans. Korea. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Aust N Z J Med. 1998 Dec;28(6):790-4 [9972408.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2688-96 [10194449.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Haematologica. 1999 May;84(5):425-30 [10329921.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1727-31 [14692525.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):23-33 [2456620.001]
  • [Cites] Br J Haematol. 1989 Jan;71(1):31-6 [2917127.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2604-12 [8453584.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):937-42 [8387578.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):513-23 [7519036.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):955-62 [8622045.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1420-32 [9414185.001]
  • (PMID = 16891805.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Other-IDs] NLM/ PMC2729883
  •  go-up   go-down


65. Benner MF, Jansen PM, Meijer CJ, Willemze R: Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol; 2009 Jul;161(1):121-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
  • BACKGROUND: CD30 is expressed in various types of cutaneous lymphomas, including lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (C-ALCL), some cases of mycosis fungoides showing large cell transformation (MF-TR) and skin localizations of systemic anaplastic lymphoma kinase (ALK)-positive or ALK-negative ALCL.
  • OBJECTIVE: To evaluate the diagnostic and prognostic significance of these markers in a large group of cutaneous CD30-positive lymphoproliferations.
  • METHODS: An immunohistochemical study on the expression of TRAF1, MUM1, BCL2 and CD15 was performed on skin biopsies from 28 patients with C-ALCL, 39 patients with LyP, 11 patients with CD30-positive MF-TR, two with ALK-positive ALCL and six with ALK-negative ALCL.
  • RESULTS: TRAF1 was expressed in roughly 70-80% and MUM1 was expressed in 70-100% of all the groups of cutaneous CD30-positive lymphoproliferations.
  • CONCLUSIONS: The results of the present study suggest that TRAF1, MUM1, BCL2 and CD15 cannot be considered as useful diagnostic or prognostic marker in cutaneous CD30-positive lymphoproliferations.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD15 / analysis. Antigens, CD30 / analysis. Biopsy. Child. Female. Humans. Immunohistochemistry / methods. Interferon Regulatory Factors / analysis. Lymphoma, Primary Cutaneous Anaplastic Large Cell / chemistry. Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Lymphoma, Primary Cutaneous Anaplastic Large Cell / immunology. Lymphomatoid Papulosis / diagnosis. Lymphomatoid Papulosis / immunology. Lymphomatoid Papulosis / metabolism. Male. Middle Aged. Mycosis Fungoides / chemistry. Mycosis Fungoides / immunology. Mycosis Fungoides / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis. TNF Receptor-Associated Factor 1 / analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416236.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TNF Receptor-Associated Factor 1; 0 / interferon regulatory factor-4
  •  go-up   go-down


66. Clarke LE, Bayerl MG, Bruggeman RD, Mauger D, Ioffreda MD, Abou-Elella A, Helm KF: Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Am J Surg Pathol; 2005 Apr;29(4):452-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
  • BACKGROUND: The CD30-positive lymphoproliferative disorders lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (C-ALCL), and systemic anaplastic large cell lymphoma (S-ALCL) are lesions that overlap clinically, histopathologically, and immunophenotypically.
  • METHODS: Dual immunohistochemistry for CD30 and activated forms of FADD and caspase 3 was performed on cutaneous biopsy specimens from 27 patients with CD30-positive lymphoproliferative disorders involving the skin.
  • The patients included 18 with primary cutaneous CD30-positive LPDs (15 with LyP and 3 with C-ALCL) and 9 with S-ALCL.
  • RESULTS: The proportion of CD30-positive cells expressing activated FADD was significantly different between primary cutaneous CD30-positive lymphoproliferative disorders and S-ALCL (36.4% vs. 14.5%, P = 0.0083).
  • CONCLUSIONS: Although a larger number of cases should be studied to validate these results, these data provide evidence that differences in signaling through the death-receptor apoptosis pathway mediated by FADD may be responsible for the varying biologic behaviors of CD30-positive lymphoproliferative disorders involving the skin.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphomatoid Papulosis / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Biopsy. Caspase 3. Caspases / metabolism. Fas-Associated Death Domain Protein. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Male. Middle Aged. Signal Transduction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767797.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / FADD protein, human; 0 / Fas-Associated Death Domain Protein; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


67. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res; 2009 Oct 1;15(19):6217-24
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.
  • PURPOSE: An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell lymphoma (pc-ALCL), lymphomatoid papulosis (LyP), or transformed mycosis fungoides (T-MF).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Large-Cell, Anaplastic / therapy. Lymphoproliferative Disorders / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Algorithms. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Immunotherapy / methods. Male. Middle Aged. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789316.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00099255
  • [Grant] United States / PHS HHS / / K24
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / SGN-30 monoclonal antibody
  •  go-up   go-down


68. Stachurski D, Miron PM, Al-Homsi S, Hutchinson L, Harris NL, Woda B, Wang SA: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24. Hum Pathol; 2007 Jun;38(6):940-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24.
  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare tumor that is frequently associated with t(2;17)(p23;q23), a translocation fusing the ALK gene at 2p23 to the clathrin heavy chain gene (CLTC) at 17q23.
  • By conventional karyotyping, the lymphoma cells were near-tetraploid and included 4 structurally normal copies each of chromosomes 2 and 17.
  • The lymphoma cells expressed CD138, lambda light chain, focal and weak CD30, and exhibited aberrant T-cell antigens, including perforin.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 4 / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Polymerase Chain Reaction. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509395.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


69. Cho SG, Koh YB, Chang HS, Park G, Kang CS, Park JW, Min WS: Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation. Eur J Haematol; 2005 Mar;74(3):259-62
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation.
  • A 25-yr-old man had been diagnosed as having CD30(+) anaplastic large cell lymphoma associated with hemophagocytic syndrome (HS).
  • He received aggressive frontline chemotherapies and consolidation with autologous peripheral blood stem cell transplantation (PBSCT) following high-dose chemotherapy combined with splenic irradiation (720 cGy in fraction of 180 cGy).
  • However, HS recurred on day 50 of PBSCT without radiologic evidence of lymphoma relapse.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / therapy. Interferon-alpha / therapeutic use. Lymphoma, Large-Cell, Anaplastic / complications. Splenectomy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Male. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction / methods

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693797.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


70. Lee HW, Kim K, Kim W, Ko YH: ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol; 2008 Jun;26(2):108-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of three cases.
  • Diffuse large B-cell lymphoma positive for anaplastic lymphoma kinase (ALK(+) DLBCL) is a rare variant of diffuse large B-cell lymphoma, with characteristic morphological, immunohistochemical and cytogenetic features.
  • Only 34 cases of ALK-positive diffuse large B-cell lymphoma have so far been reported in the literature.
  • The tumour cells showed immunoblastic/plasmablastic histology and were positive for ALK and Oct2, but negative for CD3, CD20, CD79a, CD30 and PAX5.
  • These three cases suggest that different types of cytogenetic aberrations may involve the ALK gene in ALK-positive diffuse large B-cell lymphoma leading to peculiar immunohistochemical staining patterns.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Cell Nucleus / metabolism. Chromosome Aberrations. Cytogenetics. Female. Gene Deletion. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220322.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


71. Agarwal M, Shenjere P, Blewitt RW, Hall G, Sloan P, Pigadas N, Banerjee SS: CD30-positive T-cell lymphoproliferative disorder of the oral mucosa--an indolent lesion: report of 4 cases. Int J Surg Pathol; 2008 Jul;16(3):286-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive T-cell lymphoproliferative disorder of the oral mucosa--an indolent lesion: report of 4 cases.
  • Four cases of CD30-positive T-cell lymphoproliferative disorder (CD30+ LPD) of the oral mucosa are described.
  • This article aims to draw attention to this entity and to emphasize its usual benign clinical behavior despite its resemblance to T-cell lymphoma.
  • All biopsies showed a dense lymphoid infiltrate composed of CD30+ atypical T cells with a polymorphous infiltrate in the background, which included eosinophils.
  • In 1 case, monoclonal T-cell expansion was detected by molecular techniques.
  • It is concluded that primary CD30+ T-cell LPD of the oral mucosa can be regarded as the oral counterpart of cutaneous CD30+ LPD such as lymphomatoid papulosis or anaplastic large cell lymphoma.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoproliferative Disorders / pathology. Mouth Mucosa / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Immunohistochemistry. Male. Middle Aged. Remission, Spontaneous. Tongue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387994.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


72. Momose S, Tamaru J, Kishi H, Mikata I, Mori M, Toyozumi Y, Itoyama S: Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion. Hum Pathol; 2009 Jan;40(1):75-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
  • Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma is a rare subtype of diffuse large B-cell lymphoma (DLBCL).
  • Although a few cases of ALK-positive large B-cell lymphoma harbor nucleophosmin-ALK chromosomal translocation similar to ALK-positive anaplastic large cell lymphoma, most reported cases are characterized by t(2;17)(p23;q23) involving the clathrin gene.
  • The 2 cases presented similar morphologic features and immunohistochemical characteristics, that is, positivity for ALK, IgA, CD138, and MUM1; weak positivity for CD30 and CD79a; and negativity for CD20.
  • However, there were no significant associations between expression of survivin or BCL-X(L) and ALK positivity among the diffuse large B-cell lymphomas.
  • [MeSH-major] Clathrin / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / therapeutic use. Receptor Protein-Tyrosine Kinases. Recurrence. Remission Induction. Stem Cell Transplantation. Time Factors. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18755494.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Clathrin; 0 / Oncogene Proteins, Fusion; 0 / STAT3 Transcription Factor; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


73. Zayour M, Gilmore E, Heald P, Rose M, Poligone B, Lazova R: A distinct entity in the spectrum of the CD30+ cutaneous lymphoproliferative diseases: oligolesional nodules with pseudoepitheliomatous hyperplasia followed by spontaneous resolution. Am J Dermatopathol; 2009 Feb;31(1):37-43
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A distinct entity in the spectrum of the CD30+ cutaneous lymphoproliferative diseases: oligolesional nodules with pseudoepitheliomatous hyperplasia followed by spontaneous resolution.
  • Pseudoepitheliomatous hyperplasia (PEH) in biopsies of CD30+ anaplastic large-cell lymphoma (ALCL) is present infrequently and is of unknown prognostic value and significance.
  • Biopsy specimens of all cases of CD30+ lymphoproliferative disorders (59) were retrieved from the files of Yale Dermatopathology Laboratory over a 17-year period and reviewed.
  • One patient chose to have an excision in which only a small number of CD30+ cells were present.
  • In the spectrum of CD30+ lymphoproliferative disorders, cases of ALCL with PEH are infrequent.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / pathology. Skin Diseases / complications. Skin Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperplasia. Male. Middle Aged. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155723.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


74. Lee JS, Park MY, Kim YJ, Kil HI, Choi YH, Kim YC: Histopathological features in both the eschar and erythematous lesions of Tsutsugamushi Disease: identification of CD30+ cell infiltration in Tsutsugamushi disease. Am J Dermatopathol; 2009 Aug;31(6):551-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological features in both the eschar and erythematous lesions of Tsutsugamushi Disease: identification of CD30+ cell infiltration in Tsutsugamushi disease.
  • CD30 expression is found in anaplastic large cell lymphoma; however, expression in nonneoplastic cutaneous disorders, such as atopic dermatitis, drug reactions, scabies, and various infectious diseases, has also been reported.
  • In this study, we performed biopsies of both the eschar and erythematous lesions of 15 cases of tsutsugamushi disease to assess the histopathological changes including the CD3, CD4, CD20, CD30, and CD68 reactivity.
  • Seven erythematous lesions and 7 eschar lesions showed atypical cells that were CD30-positive cells.
  • In addition, CD30-positive cell infiltration was identified for the first time in this disease.
  • [MeSH-major] Antigens, CD30 / immunology. Scrub Typhus / immunology. Scrub Typhus / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Immunophenotyping. Leukocytes, Mononuclear / immunology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19590420.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


75. Humme D, Lukowsky A, Steinhoff M, Beyer M, Walden P, Sterry W, Assaf C: Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders. J Invest Dermatol; 2009 Jan;129(1):89-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders.
  • The CD30-positive cutaneous lymphoproliferative disorders (CLPD) include lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL).
  • Even after years of clinical remission newly erupting lesions often harbor a T-cell clone identical to the initial one.
  • This fact raises the question whether the clonal T-cell population persists in the peripheral blood.
  • We performed molecular genetic analysis by combining T-cell receptor (TCR)-gamma PCR with the GeneScan technique and assessed the TCR repertoire in selected blood samples by beta-variable complementarity-determining region 3 (CDR3) spectratyping qualitatively and quantitatively.
  • We were able to detect a clonal T-cell population in 36/43 (84%) skin samples and in 35/83 (42%) blood samples.
  • Comparison of the compartments in each patient demonstrated different T-cell clones in skin and blood, suggesting a reactive nature of the clonal T cells in the blood.
  • Moreover, CDR3 spectratyping revealed a restricted T-cell repertoire in the blood, suggesting T-cell stimulation by an unknown antigen.
  • [MeSH-major] Antigens, CD30 / biosynthesis. Complementarity Determining Regions / immunology. Lymphoma, T-Cell / immunology. Receptors, Antigen, T-Cell / metabolism. T-Lymphocytes / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Models, Biological. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633437.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Complementarity Determining Regions; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


76. Bovio IM, Allan RW: The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. Am J Clin Pathol; 2008 Oct;130(4):628-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas.
  • We retrospectively studied the immunophenotype by flow cytometry of 20 anaplastic large cell lymphomas (ALCLs) (9 anaplastic lymphoma kinase [ALK]+ and 11 ALK-) with a particular emphasis on the aberrant expression of the myeloid associated antigens CD13 and/or CD33.
  • All ALCLs expressed CD45, HLA-DR, and CD30.
  • Most (8/9) ALK+ ALCLs expressed at least 1 surface T-cell antigen (CD4, 6/9 [67%]; CD7, 6/9 [67%]; CD2, 5/9 [56%]; CD5, 2/9 [22%]; CD8, 2/9 [22%]; CD3, 1/9 [11%]).
  • All ALK-ALCLs expressed at least 1 surface T-cell antigen (CD3, 7/11 [64%]; CD4, 6/11 [55%]; CD2, 6/11 [55%]; CD7, 2/11 [18%]; CD5, 1/11 [9%]; CD8, 1/11 [9%]).
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Biomarkers, Tumor / analysis. Lymphoma, Large-Cell, Anaplastic / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Infant. Male. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Sialic Acid Binding Ig-like Lectin 3

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794057.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


77. Schlaf G, Altermann WW, Rothhoff A, Seliger B: Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs? Histol Histopathol; 2007 11;22(11):1269-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs?
  • The CD30 molecule, a 120 kDa cell surface glycoprotein, is a member of the tumor necrosis factor receptor (TNF-R) superfamily and was originally identified on the surface of Reed-Sternberg cells and anaplastic large cell lymphomas in Hodgkin's disease patients.
  • In addition to lymphoproliferative disorders the expression of CD30 was found in both activated CD8+ and CD4+ Th2 cells which lead to the activation of B-cells and consequently to the inhibition of the Th1-type cellular immunity.
  • The membrane-bound CD30 molecule can be proteolytically cleaved, thereby generating a soluble form (sCD30) of about 85 kDa.
  • Low serum levels of soluble CD30 were found in healthy humans, whereas increased sCD30 serum concentrations were detected under pathophysiological situations such as systemic lupus erythematosus, rheumatoid arthritis, certain viral infections and adult T cell leukaemia/lymphoma.
  • [MeSH-major] Antigens, CD30 / blood. Biomarkers / blood. Graft Rejection / blood. Graft Rejection / diagnosis. Monitoring, Immunologic / methods. Organ Transplantation

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17647199.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers
  • [Number-of-references] 76
  •  go-up   go-down


78. Zhang D, Denley RC, Filippa DA, Teruya-Feldstein J: ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23). Appl Immunohistochem Mol Morphol; 2009 Mar;17(2):172-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23).
  • Diffuse large B-cell lymphoma (DLBCL) with plasmablastic features associated with t(2;17)(p23;q23) and characteristic granular cytoplasmic anaplastic lymphoma kinase-1 (ALK1) protein expression is a rare lymphoma subtype.
  • Lymph node biopsy showed large atypical cells with prominent plasmablastic differentiation, abundant amphophilic cytoplasm, and prominent central nucleoli.
  • Paraffin immunohistochemistry showed finely granular cytoplasmic ALK1 expression, positive CD138, IgA, p63 (VS38), focal positive epithelial membrane antigen and CD4, and lambda light chain restriction whereas negative CD20 and CD30 staining.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521280.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


79. Reichard KK, McKenna RW, Kroft SH: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol; 2007 Mar;20(3):310-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • We report detailed clinical and pathologic features of four cases of anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL), a rare entity with only 29 currently reported cases.
  • Biopsies from four adult patients aged 41, 49, 53, and 71 years (three lymph nodes and one nasopharyngeal mass) exhibited immunoblastic/plasmablastic morphology.
  • By immunohistochemistry and/or flow cytometry, they expressed cytoplasmic ALK-1, CD138, VS38 (3/3), monoclonal cytoplasmic light chain, CD45, EMA, CD4, and CD57 (2/3), and were negative for CD3, CD30, CD56, and TIA-1.
  • [MeSH-major] Lymphoma, B-Cell / enzymology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Flow Cytometry. Humans. Immunohistochemistry. Male. Middle Aged. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277765.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


80. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol; 2009;2:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • BACKGROUND: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL).
  • By immunohistochemistry, cases were positive for cytoplasmic ALK, MUM1, CD45, and EMA; they marked negative for CD3, CD30 and CD20.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Female. Humans. Interferon Regulatory Factors / metabolism. Male. Prognosis. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2001 Mar;115(3):396-403 [11242796.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):357-63 [16091196.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):529-34 [17134546.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):166-9 [17635242.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):126-44 [18039352.001]
  • [Cites] Korean J Lab Med. 2008 Apr;28(2):89-94 [18458503.001]
  • [Cites] Biochem J. 2008 Jun 15;412(3):415-23 [18498251.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • (PMID = 19250532.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2651189
  •  go-up   go-down


81. Tamiolakis D, Papadoupoulos N, Venizelos I, Lambropoulou M, Tsikouras P, Koutsougeras G, Bolioti S, Tsiapali M, Karpouzis A, Kouskoukis C: CD30 (Ki-1) molecule expression in human embryonal epithelial cells of the basal layer of the developing epidermis and epidermal buds and its potential significance for embryogenesis. Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep;14(3):85-90, 92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30 (Ki-1) molecule expression in human embryonal epithelial cells of the basal layer of the developing epidermis and epidermal buds and its potential significance for embryogenesis.
  • OBJECTIVE: CD30 antigen has long been considered to be restricted to tumour cells of Hodgkin's disease, of anaplastic large cell lymphoma and T and B activated lymphocytes.
  • Expression of CD30 antigen has been reported in the decidual stroma, cultivated macrophages, lipoblasts, myoepithelial cells, reactive and neoplastic vascular lesions, mesotheliomas, embryonal carcinoma and seminoma cells.
  • The fact that the CD30 molecule can mediate signals for cell proliferation or apoptosis prompted us to perform a systematic investigation of CD30 antigen expression in embryonal tissues during the proliferation and differentiation stages.
  • This rapid replacement demands, as with other epithelial tissues, that an adult has stem cells capable of supplying differentiated cells throughout life.
  • Not all of the proliferative cells in the basal layer are stem cells and we were intrigued to find out if stem or other cells in the basal layer can express the CD30 antigen.
  • MATERIALS AND METHODS: We investigated the immunohistochemical expression of CD30 antigen in 15 paraffin-embedded tissue samples representing epidermis and epidermal buds from foetuses after spontaneous abortion in 8th, 10th, and 12th week of gestation, respectively, using the monoclonal antibody Ki-1.
  • RESULTS: The results showed that the epithelial cells of the epidermis in the developing skin express the CD30 antigen and CD30 expression in these epithelial cells is higher in cases of hormonal administration than in normal gestation.
  • [MeSH-major] Antigens, CD30 / metabolism. Epidermis / metabolism. Epithelial Cells / metabolism. Fetus / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Papadopoulos N. Acta Dermatovenerol Alp Pannonica Adriat. 2009 Sep;18(3):144 [19784532.001]
  • (PMID = 16200333.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


82. Kansal R, Sait SN, Block AW, Ward PM, Kelly FL, Cheney RT, Czuczman M, Brecher ML, Barcos M: Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology. Mod Pathol; 2005 Feb;18(2):235-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology.
  • The purpose of this study was to evaluate fluorescence in situ hybridization abnormalities of the 2p23 anaplastic lymphoma kinase (ALK) gene loci in lymphomas with anaplastic morphology.
  • We studied 24 anaplastic large cell lymphomas (ALCL) classified by World Health Organization criteria [17 primary nodal/systemic (10 ALK+, 7 ALK-), seven primary cutaneous], and 17 additional non-Hodgkin's lymphomas [one ALK+ B-lineage lymphoma, 14 ALK- diffuse large B-cell lymphomas (seven anaplastic variants, five nonanaplastic, two secondary CD30+), two follicular lymphomas].
  • ALK- lymphomas with anaplastic morphology showed extra nonrearranged anaplastic lymphoma kinase gene loci (P=0.004) due to trisomy 2 irrespective of the following factors: B or T/null phenotype (P=0.315), diagnostic categories of systemic or cutaneous ALCL or the above-mentioned B-cell lymphomas (P=0.131), and CD30 positivity by immunohistochemistry (P=1.000).
  • Its presence in secondary B-cell lymphomas suggests that trisomy 2 may be a secondary cytogenetic aberration in lymphomas in general.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 2 / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Antigens, CD15 / analysis. Antigens, CD30 / analysis. Child. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Mucin-1 / analysis. Receptor Protein-Tyrosine Kinases. Statistics as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475930.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


83. Bittencourt AL, Barbosa HS, Vieira MD, Farré L: Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases. Acta Oncol; 2009;48(4):598-604
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATL) is a severe disease caused by HTLV-I.
  • Immunohistochemistry was performed using CD3, CD4, CD5, CD7, CD8, CD20, CD25, CD30 and CD45RO markers.
  • Patterns resembling mycosis fungoides (MF) were found in 19 cases and anaplastic large-cell lymphoma (ALCL) in two cases.
  • [MeSH-major] Antigens, CD8 / analysis. CD8-Positive T-Lymphocytes / virology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / mortality. Skin Neoplasms / diagnosis. Skin Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Cell Proliferation. Child. Female. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Male. Middle Aged. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165640.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8; 0 / Ki-67 Antigen
  •  go-up   go-down


84. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, Bernstein SH, Bociek RG, Lorenz JM, Hart BW, Barton J: A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood; 2008 Feb 15;111(4):1848-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
  • Phase 1 testing of SGN-30, a chimeric monoclonal antibody for the treatment of CD30(+) malignancies, was conducted in a multicenter study.
  • To explore the safety profile and establish the maximum tolerated dose (MTD), 24 patients with refractory or relapsed Hodgkin lymphoma or CD30(+) non-Hodgkin lymphoma received 6 weekly doses of intravenous SGN-30 at 4 dose levels (2, 4, 8, or 12 mg/kg).
  • One patient with cutaneous anaplastic large cell lymphoma (8 mg/kg) achieved a complete response.
  • Six patients, of whom 4 had Hodgkin lymphoma, achieved stable disease with durations ranging from 6 to 16 months.
  • These results demonstrate that weekly administration of SGN-30 is safe and has modest clinical activity in patients with CD30(+) tumors.
  • [MeSH-major] Antibodies, Monoclonal / toxicity. Antigens, CD30 / blood. Hematologic Neoplasms / drug therapy. Immunotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Antibodies / blood. Antigens, CD / blood. Female. Humans. Male. Middle Aged. Monitoring, Physiologic. Patient Selection. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 2002 Jun;77(6):522-30 [12059121.001]
  • [Cites] Ann Intern Med. 2006 Aug 1;145(3):204-8 [16880462.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1769-78 [15858186.001]
  • [Cites] Lancet. 2007 Dec 1;370(9602):1855-60 [18061062.001]
  • [Cites] Ann Intern Med. 2000 Sep 5;133(5):329-37 [10979877.001]
  • (PMID = 18079362.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00051597
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD30; 0 / SGN-30 monoclonal antibody
  • [Other-IDs] NLM/ PMC2275000
  •  go-up   go-down


85. Greisser J, Palmedo G, Sander C, Kutzner H, Kazakov DV, Roos M, Burg G, Kempf W: Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders. J Cutan Pathol; 2006 Nov;33(11):711-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
  • Monoclonal rearrangement of T-cell receptor genes (TCR) was reported in fresh frozen tissue of lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (ALCL), but the diagnostic value of T-cell clonality in formalin-fixed, paraffin-embedded biopsies has so far not been assessed.
  • CONCLUSIONS: T-cell clonality can only be found in a minority (four of 18; 22%) of archival LyP specimens, even when employing a highly sensitive detection method and is thus of limited diagnostic value.
  • [MeSH-major] Antigens, CD30 / genetics. Gene Rearrangement, T-Lymphocyte / genetics. Lymphoproliferative Disorders / diagnosis. Receptors, Antigen, T-Cell / genetics. Skin Diseases, Genetic / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA / genetics. DNA Fragmentation. DNA, Neoplasm / genetics. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, T-Cell, Cutaneous / diagnosis. Lymphoma, T-Cell, Cutaneous / genetics. Lymphomatoid Papulosis / diagnosis. Lymphomatoid Papulosis / genetics. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083688.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / DNA, Neoplasm; 0 / Receptors, Antigen, T-Cell; 9007-49-2 / DNA
  •  go-up   go-down


86. Choung HS, Kim HJ, Kim WS, Kim K, Kim SH: [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]. Korean J Lab Med; 2008 Apr;28(2):89-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement].
  • Aanaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is an unusual disease entity first reported in 1997 as DLBCL with expression of full-length ALK protein.
  • Immunohistochemical studies on the lymph nodes revealed large sized neoplastic cells with plasmablastic differentiation, which were negative for CD30 and positive for ALK with the characteristic granular staining in the cytoplasmic region.
  • Extensive involvement of bone marrow was observed in both cases showing large, extremely atypical cells.
  • [MeSH-major] Bone Marrow / pathology. Clathrin / genetics. Gene Fusion. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458503.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Clathrin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


87. Li D, Li GD, Liu WP, Zhang WY, Li FY, Liao DY: [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas]. Zhonghua Xue Ye Xue Za Zhi; 2005 Apr;26(4):223-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas].
  • OBJECTIVE: To explore the prognostic factors of primary nodal diffuse large B-cell lymphomas (N-DLBCL).
  • Antibodies used for study were anti-CD20, CD79alpha, CD45RO, CD3, Bcl-2, Ki-67, CD30, CD15, kappa, lambda, Cyclin D1, TdT, GFAP, CK, MPO.
  • RESULTS: Of the 51 cases of N-DLBCLs, 40 were reclassified as centroblastic, 3 B-immunoblastic, 1 T-cell/histiocytes rich, 2 B-cell anaplastic large cell, 1 plasmablastic, and 4 unclassified.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD15 / analysis. Antigens, CD20 / analysis. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Child. Child, Preschool. Cyclin D1 / analysis. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Prognosis. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949265.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


88. Laharanne E, Chevret E, Idrissi Y, Gentil C, Longy M, Ferrer J, Dubus P, Jouary T, Vergier B, Beylot-Barry M, Merlio JP: CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol; 2010 Apr;23(4):547-58
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.
  • Inactivation of the CDKN2A-CDKN2B locus has been reported in the most frequent subtypes of cutaneous T-cell lymphomas (CTCLs), mycosis fungoides, Sézary syndrome (SS) and CD30+ cutaneous anaplastic large cell lymphoma.
  • We studied 67 samples from 58 patients with either transformed mycosis fungoides (n=24), SS (n=16) or CD30+ cutaneous anaplastic large cell lymphoma (n=18).
  • We observed combined CDKN2A-CDKN2B deletion in both transformed mycosis fungoides (n=17, 71%) and SS patients (n=7, 44%), but, surprisingly, in only one CD30+ cutaneous anaplastic large cell lymphoma case.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Genes, p16. Lymphoma, T-Cell, Cutaneous / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Comparative Genomic Hybridization. DNA Methylation. Female. Gene Deletion. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p14ARF / genetics. Young Adult

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118908.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Tumor Suppressor Protein p14ARF
  •  go-up   go-down


89. Slack GW, Ferry JA, Hasserjian RP, Sohani AR, Longtine JA, Harris NL, Zukerberg LR: Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis. Leuk Lymphoma; 2009 Jun;50(6):937-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis.
  • Lymphocyte depleted classical Hodgkin lymphoma (LDHL) is a vanishing category of classical Hodgkin lymphoma (CHL); many cases previously placed in this category are now recognised as diffuse large B-cell lymphoma (DLBCL), anaplastic large-cell lymphoma (ALCL), or nodular sclerosis CHL with lymphocyte depletion.
  • In addition, the recent recognition of high grade B-cell lymphomas intermediate between DLBCL and CHL (grey-zone lymphomas) raises the question of whether LDHL exists at all as a category of CHL.
  • In three cases the tumors had a more diffuse fibrotic appearance, while in five cases they appeared reticular and anaplastic.
  • Neoplastic cells in all cases expressed CD30, CD15, fascin, weak PAX5 and MUM-1 and lacked CD45, Alk-1, EMA, CD3, CD68, Mart-1 and cytokeratin.
  • [MeSH-minor] Adult. Aged. Antigens, CD15 / analysis. Antigens, CD30 / analysis. B-Cell-Specific Activator Protein / analysis. Carrier Proteins / analysis. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Interferon Regulatory Factors / analysis. Male. Microfilament Proteins / analysis. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455461.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / B-Cell-Specific Activator Protein; 0 / Carrier Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Interferon Regulatory Factors; 0 / Microfilament Proteins; 0 / PAX5 protein, human; 0 / interferon regulatory factor-4; 146808-54-0 / fascin
  •  go-up   go-down


90. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N: Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):51-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
  • PURPOSE: The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL).
  • RESULTS: Two patients with CD30+ anaplastic large T-cell lymphoma and 31 with mycosis fungoides (stage IB [T2, n = 2], stage IIA [T2, n = 1], stage IIB [T3, n = 13], stage IVA [T3 N3, n = 3; T4b2, n = 2; T4b2 N3, n = 2], and stage IVB [T4b2 N1, n = 6; T4 N3b2 M1, n = 1; T3 N3 M1, n = 1]) had received a median of 5 previous therapies (range, 1-13 therapies).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Mycosis Fungoides / complications. Receptors, Interleukin-2 / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879770.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Interleukin-2; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


91. Wang HY, Fuda FS, Chen W, Karandikar NJ: Notch1 in primary effusion lymphoma: a clinicopathological study. Mod Pathol; 2010 Jun;23(6):773-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch1 in primary effusion lymphoma: a clinicopathological study.
  • Primary effusion lymphoma is a human herpes virus 8 (HHV-8)-associated large cell lymphoma of body cavities.
  • Detailed large-scale clinicopathological studies are rarely reported, and the underlying mechanism of lymphomagenesis remains elusive.
  • In the present report, we studied the clinicodemographic, immunophenotypic, and cytomorphological features on a cohort of 12 cases of primary effusion lymphoma.
  • By flow cytometry, the antigens expressed in descending order were CD38, CD71, HLA-DR, CD30, and CD45RO.
  • B-cell markers were largely negative.
  • Cytomorphologically, all cases showed atypical to anaplastic morphology.
  • In agreement with in vitro studies using human primary effusion lymphoma cell lines, we have found that Notch1 was expressed in the majority of HHV-8-positive primary effusion lymphoma cases, corroborating the notion that Notch1 may have an important role in HHV-8-mediated lymphomagenesis of primary effusion lymphoma.
  • [MeSH-major] Lymphoma, Primary Effusion / chemistry. Receptor, Notch1 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD30 / analysis. Antigens, CD38 / analysis. Antigens, CD45 / analysis. DNA, Viral / analysis. Female. Flow Cytometry. Gene Rearrangement. Genes, T-Cell Receptor. HIV / isolation & purification. HLA-DR Antigens / analysis. Herpesvirus 4, Human / genetics. Herpesvirus 8, Human / genetics. Herpesvirus 8, Human / isolation & purification. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Male. Membrane Glycoproteins / analysis. Middle Aged. Polymerase Chain Reaction. Prognosis. Receptors, Transferrin / analysis

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2010 Jul;23(7):1043
  • (PMID = 20348880.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; 0 / CD71 antigen; 0 / DNA, Viral; 0 / HLA-DR Antigens; 0 / Immunoglobulin Heavy Chains; 0 / Membrane Glycoproteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / Receptors, Transferrin; EC 3.1.3.48 / Antigens, CD45; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


92. Coors EA, Schuler G, Von Den Driesch P: Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol; 2006 Jul-Aug;16(4):391-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod as treatment for different kinds of cutaneous lymphoma.
  • Apart from its use for genital warts it has therefore been used as treatment for different cutaneous neoplasms, including a few cases of cutaneous T-cell lymphoma.
  • We treated 8 patients (4 with mycosis fungoides, 1 with CD30+ anaplastic large cell lymphoma and 3 with primary cutaneous B-cell lymphoma) with topical imiquimod.
  • Two patients with mycosis fungoides and the patient with the CD30+ anaplastic large cell lymphoma had a complete clinical remission, the other two patients with mycosis fungoides did not show a response to imiquimod.
  • Of the patients with cutaneous B-cell lymphoma, two reached a partial remission, one did not respond to therapy.
  • Our preliminary data show that imiquimod might be effective in some cases with therapy resistant lesions of cutaneous T-cell lymphoma as well as of cutaneous B-cell lymphoma, but more controlled studies are needed.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Dermatol. 2008 Jul-Aug;18(4):467-8 [18573730.001]
  • (PMID = 16935796.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


93. Saggini A, Gulia A, Argenyi Z, Fink-Puches R, Lissia A, Magaña M, Requena L, Simonitsch I, Cerroni L: A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol; 2010 Aug;34(8):1168-75
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.
  • Lymphomatoid papulosis (LyP) is a recurrent, self-healing eruption belonging to the spectrum of cutaneous CD30+lymphoproliferative disorders.
  • Three main histologic subtypes of LyP are recognized: type A (histiocytic), type B (mycosis fungoides-(MF)-like), and type C (anaplastic large cell lymphoma-like).
  • We reviewed 26 biopsies from 9 patients (M:F=6:3, median age: 29; mean age 27,2; age range 10 to 38) who presented with clinical features typical of LyP but with histopathologic aspects that resembled primary cutaneous aggressive epidermotropic CD8+cytotoxic T-cell lymphoma.
  • In all but 1 case atypical lymphoid cells showed expression of CD30, and in 8 of 9 cases a T-cell cytotoxic phenotype could be observed (betaF1+, CD3+, CD4-, CD8+).
  • Polymerase chain reaction analysis of the T-cell receptor genes revealed a monoclonal rearrangement in 2 of 5 cases tested.
  • This cytotoxic variant of LyP may be histopathologically indistinguishable from primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, and may be the source of pitfalls in the diagnosis and classification.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / diagnosis. Lymphomatoid Papulosis / diagnosis. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Adolescent. Adult. Biopsy. Child. Diagnosis, Differential. Female. Genes, T-Cell Receptor gamma. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Male. Polymerase Chain Reaction. RNA, Viral / analysis. Terminology as Topic. Young Adult

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661014.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral
  •  go-up   go-down


94. Morizane S, Setsu N, Yamamoto T, Hamada T, Nakanishi G, Asagoe K, Iwatsuki K: Ichthyosiform eruptions in association with primary cutaneous T-cell lymphomas. Br J Dermatol; 2009 Jul;161(1):115-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ichthyosiform eruptions in association with primary cutaneous T-cell lymphomas.
  • BACKGROUND: Malignant lymphoma is occasionally complicated by ichthyosiform eruptions.
  • METHODS: We reviewed the files of patients with malignant lymphoma seen in our dermatology department between January 2001 and May 2006 to search for patients with ichthyosiform eruptions.
  • RESULTS: In our series, nine of 106 patients with malignant lymphomas had ichthyosiform eruptions during their clinical courses, including three (30%) of 10 patients with anaplastic large cell lymphoma (ALCL) and six (14%) of 44 patients with mycosis fungoides (MF).
  • None of the 18 patients with cutaneous B-cell lymphoma had ichthyosiform eruptions.
  • These two patients (stages IVa and IIb) had tumours composed of CD30+ cells.
  • CONCLUSIONS: Ichthyosiform eruptions are often associated with ALCL and MF and can be classified into three groups: AI associated with ALCL and MF expressing CD30, IMF, and their overlap.
  • [MeSH-major] Ichthyosis / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / immunology. Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Male. Middle Aged. Mycosis Fungoides / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416265.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Intermediate Filament Proteins; 0 / filaggrin
  •  go-up   go-down


95. Gualco G, Bacchi CE: B-cell and T-cell lymphomas of the breast: clinical--pathological features of 53 cases. Int J Surg Pathol; 2008 Oct;16(4):407-13
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell and T-cell lymphomas of the breast: clinical--pathological features of 53 cases.
  • Most of the cases were of B-cell phenotype.
  • Four of the patients with primary breast lymphomas had T-cell lymphomas, 3 had CD30-positive anaplastic large cell lymphomas, and 1 had panniculitis-like T-cell lymphoma.
  • Secondary breast lymphoma was seen in 19 patients and most commonly occurred as part of widespread nodal disease.
  • The most prevalent histological subtype was also diffuse large B-cell lymphoma, followed by follicular lymphoma.
  • This study shows that the broad morphological and immunophenotypical spectrum of malignant lymphoma of the breast occurring in a large series of Brazilian patients has many similarities with that seen in Western countries, with a higher proportion of high-grade lymphomas in both primary and secondary cases.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms, Male / pathology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480397.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 070058; United States / NCI NIH HHS / CA / CA082274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


96. Carmichael MG: Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy. Mil Med; 2007 Jun;172(6):673-5
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
  • Anaplastic large cell lymphoma (ALCL) is 1 of 17 mature T cell neoplasms described by the World Health Organization.
  • Primary central nervous system (PCNS) ALCL represents a distinct rare form of this family of non-Hodgkin lymphoma and discussions of prognosis and management are limited to case reports and case series.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dexamethasone / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615857.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


97. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K: Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int; 2008 Feb;58(2):89-97

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.
  • Although various CD markers have been analyzed in T-cell and natural killer (NK)-cell lymphomas, the sensitivity and specificity of these phenotypic features have not been satisfactorily characterized.
  • Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56).
  • In data obtained from 319 patients, CD10 expression was detected in 57% of angioimmunoblastic T-cell lymphomas, CD30 in 93% of anaplastic large cell lymphomas, CD34 in 50% of lymphoblastic lymphomas, and CD56 in 100% of extranodal NK/T-cell lymphomas nasal type.
  • A total of 92% of adult T-cell leukemia/lymphomas (ATLL) had expression of CD25 and downregulation of CD7.
  • Of special interest is that 92 ATLL (50%) were CD4+CD7-CD25+ phenotype while only four peripheral T-cell lymphoma unspecified (9%) and one (9%) cutaneous T-cell lymphoma had this phenotype.
  • Phenotypic analysis using FCM was thus found to be useful for differential diagnosis of T-cell and NK-cell lymphomas.
  • [MeSH-major] Flow Cytometry / methods. Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199158.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Wasco MJ, Fullen D, Su L, Ma L: The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol; 2008 Apr;39(4):557-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.
  • It is normally expressed in plasma cells, late B cells, and activated T cells, and has been described in several B-cell malignancies.
  • Although its expression has been reported in some T-cell neoplasms, the full range and character of expression have not been explored.
  • We studied 58 cases of T-cell lymphoproliferative lesions, including systemic and cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis (LyP), mycosis fungoides (MF), MF with large cell transformation, and Sézary syndrome (SS).
  • Nearly all cutaneous (5/5) and systemic anaplastic large cell lymphomas (4/5) were positive for MUM1, mainly in the large cell population.
  • Similarly, 12 of 16 types A and C LyP showed MUM1 reactivity in greater than 50% of the large cells.
  • All 9 MF with large cell transformation expressed MUM1 in large cells, where it paralleled CD30 expression.
  • There was a significant difference in MUM1 expression between MF and SS groups as well as between MF and large cell transformation of MF groups (P < .001 for both).
  • In summary, MUM1 is not helpful in separating different types of CD30-positive lymphoproliferative disorders.
  • Potentially, MUM1 could serve as an adjunct marker for SS and/or large cell transformation of MF.
  • [MeSH-major] Biomarkers, Tumor / analysis. Interferon Regulatory Factors / analysis. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234282.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4
  •  go-up   go-down


99. Hallermann C, Schulze HJ, Neumann C, Klemke CD: The regulatory T-cell phenotype in progressive mycosis fungoides. G Ital Dermatol Venereol; 2008 Feb;143(1):15-9
Genetic Alliance. consumer health - Mycosis fungoides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The regulatory T-cell phenotype in progressive mycosis fungoides.
  • In most of those cases the lymphoma cells express CD25.
  • [MeSH-minor] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Clone Cells / pathology. Cohort Studies. Disease Progression. Forkhead Transcription Factors / analysis. Forkhead Transcription Factors / genetics. Forkhead Transcription Factors / physiology. Humans. Immune Tolerance. Immunocompromised Host. Immunophenotyping. Interleukin-2 Receptor alpha Subunit / analysis. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Neoplastic Stem Cells / pathology. Sezary Syndrome / immunology. Sezary Syndrome / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833048.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, Neoplasm; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Neoplasm Proteins
  • [Number-of-references] 41
  •  go-up   go-down


100. Yagi H, Seo N, Ohshima A, Itoh T, Itoh N, Horibe T, Yoshinari Y, Takigawa M, Hashizume H: Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. Am J Surg Pathol; 2006 Sep;30(9):1111-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.
  • Interactions between chemokines and chemokine receptors are involved in migration and invasion of lymphoma cells.
  • We investigated expression profiles of CXCR3 and CCR4 by immunohistochemistry and flow cytometry, and their biologic behaviors by real-time horizontal chemotaxis assay in cutaneous T cell and NK/T-cell lymphomas (TCLs).
  • CD30 cells exclusively expressed CCR4 in anaplastic large-cell lymphoma, and CXCR3 and/or CCR4 in lymphomatoid papulosis.
  • Therefore, spatial and temporal interactions between chemokine receptors and their ligands seem to dictate recruitment and retention of lymphoma cells in the skin.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell, Cutaneous / chemistry. Receptors, Chemokine / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotaxis / physiology. Female. Flow Cytometry. Humans. Immunohistochemistry. Lymphatic Diseases / metabolism. Lymphoma, Large B-Cell, Diffuse / chemistry. Male. Middle Aged. Mycosis Fungoides / chemistry. Receptors, CCR4. Receptors, CXCR3

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931956.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / CXCR3 protein, human; 0 / Receptors, CCR4; 0 / Receptors, CXCR3; 0 / Receptors, Chemokine
  •  go-up   go-down






Advertisement